Funders › NY › The Leona M and Harry B Helmsley Charitable Trust › 2022
Grants paid by The Leona M and Harry B Helmsley Charitable Trust, tax year 2022
EIN 13-7184401 · New York, NY · Form 990-PF, Part XV · NTEE T20
In tax year 2022, The Leona M and Harry B Helmsley Charitable Trust (EIN 13-7184401) reported 544 grants paid totaling $385,014,429. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2022 · page 1 of 2
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $15,576,000 | paid | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $12,644,876 | paid | MINNESOTA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $9,908,264 | paid | THE HELMSLEY CANCER CENTER AT SHAARE ZEDEK MEDICAL CENTER JERUSALEM | 202300389349100520 |
| 2022 | Engineering Ministries International USA Colorado Springs, CO | B | $7,020,410 | approved, future | ALASKA WASH PROJECT | 202300389349100520 |
| 2022 | Engineering Ministries International USA Colorado Springs, CO | B | $6,680,429 | paid | ALASKA WASH PROJECT | 202300389349100520 |
| 2022 | Yitzhak Shamir Medical Center Tzrifin | U | $6,082,143 | approved, future | EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $6,054,477 | approved, future | PEN-PLUS EXPANSION | 202300389349100520 |
| 2022 | Nebraska Department of Health & Human Services Lincoln, NE | U | $5,608,814 | paid | NEBRASKA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Jerusalem College of Technology Jerusalem | U | $5,465,000 | approved, future | HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING | 202300389349100520 |
| 2022 | The Baruch Padeh Medical Center Poriya Tiberias | U | $5,431,730 | approved, future | THE HELMSLEY REHABILITATION CENTER OF THE NORTH | 202300389349100520 |
| 2022 | Iowa Department of Public Health Des Moines, IA | U | $5,283,804 | paid | IOWA FIRST RESPONDER AED INITIATIVE | 202300389349100520 |
| 2022 | Bridges to Prosperity Inc Denver, CO | D | $5,262,850 | paid | TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $5,226,272 | approved, future | THE HELMSLEY CANCER CENTER AT SHAARE ZEDEK MEDICAL CENTER JERUSALEM | 202300389349100520 |
| 2022 | The Baruch Padeh Medical Center Poriya Tiberias | U | $5,115,157 | paid | THE HELMSLEY REHABILITATION CENTER OF THE NORTH | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $5,026,234 | approved, future | REDEFINING THE FUTURE OF EMERGENCY MEDICINE | 202300389349100520 |
| 2022 | Civica Foundation Lehi, UT | B | $5,000,000 | paid | AFFORDABLE INSULIN BIOSIMILARS | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $4,885,390 | approved, future | MINNESOTA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $4,470,844 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $4,470,844 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $4,470,843 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | The Baruch Padeh Medical Center Poriya Tiberias | U | $4,453,113 | approved, future | THE HELMSLEY REHABILITATION CENTER OF THE NORTH | 202300389349100520 |
| 2022 | Zefat Academic College Zefat | U | $4,114,152 | paid | EQUIPPING ZEFAT ACADEMIC COLLEGE'S INST. FOR ADV. HEALTH TRAINING & ED. | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $3,896,000 | paid | MEDICAL EQUIPMENT FOR CARMEL MEDICAL CENTER IN HAIFA, ISRAEL | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $3,847,500 | approved, future | YOSEFTAL HOSPITAL ADDITION | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $3,802,596 | approved, future | PEN-PLUS EXPANSION | 202300389349100520 |
| 2022 | T1d Exchange Inc Boston, MA | U | $3,686,424 | paid | DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,653,834 | paid | IDENTIFICATION OF INFANTS WITH HIGH RISK OF T1D - PRIMARY PREVENTION | 202300389349100520 |
| 2022 | Maccabi Healthcare Services Tel Aviv | U | $3,505,000 | paid | DA VINCI 4XI SYSTEM DUAL CONSOLE SURGICAL ROBOT AND STERILIZATION EQUIP. | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $3,500,000 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $3,480,533 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $3,480,533 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | Indiana University Indianapolis, IN | C | $3,474,440 | paid | AMPATH MODEL REPLICATION IN GHANA | 202300389349100520 |
| 2022 | Central Montana Medical Facilities Inc Lewistown, MT | B | $3,469,965 | approved, future | CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER | 202300389349100520 |
| 2022 | New Venture Fund Washington, DC | B | $3,302,000 | paid | TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024) | 202300389349100520 |
| 2022 | Renown Health Foundation Reno, NV | C | $3,099,867 | approved, future | SIMULATION LAB AND INNOVATION CENTER | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,074,101 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,074,100 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $3,031,033 | paid | GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $3,000,000 | paid | NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE | 202300389349100520 |
| 2022 | Jdrf T1d Fund LLC Boston, MA | U | $3,000,000 | paid | JDRF T1D FUND PHASE III | 202300389349100520 |
| 2022 | South Dakota Parks & Wildlife Foundation Pierre, SD | B | $3,000,000 | paid | CUSTER STATE PARK BISON CENTER | 202300389349100520 |
| 2022 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $3,000,000 | paid | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202300389349100520 |
| 2022 | Children's Mercy Hospital Kansas City, MO | B | $2,966,873 | approved, future | TYPE 1 DIABETES RAPID LEARNING LAB | 202300389349100520 |
| 2022 | Kmr Advancement of Medical Centers Ltd Haifa | U | $2,950,750 | paid | ESTABLISHMENT OF THE HEALTH DISCOVERY TOWER | 202300389349100520 |
| 2022 | Jerusalem College of Technology Jerusalem | U | $2,859,000 | paid | HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING | 202300389349100520 |
| 2022 | Wateraid America Inc New York, NY | B | $2,839,148 | paid | CREATING A NEW REALITY FOR WASH IN HEALTHCARE FACILITIES IN ZAMBIA | 202300389349100520 |
| 2022 | Bridges to Prosperity Inc Denver, CO | D | $2,812,542 | approved, future | TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $2,752,636 | paid | COMMUNITY RECOVERY AND RESILIENCE IN EASTERN ETHIOPIA | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,705,330 | paid | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | Bridges to Prosperity Inc Denver, CO | D | $2,648,126 | approved, future | TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,622,774 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,622,773 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | Israel Antiquities Authority Jerusalem | U | $2,600,000 | paid | JAY & JEANIE SCHOTTENSTEIN NATIONAL CAMPUS FOR THE ARCHAEOLOGY OF ISRAEL | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $2,589,304 | paid | INTEGRATED COMMUNITY WATER, SANITATION AND HYGIENE IMPROVEMENT IN GHANA | 202300389349100520 |
| 2022 | Schwartzreisman Science Education Center Rehovot Rehovot | U | $2,540,089 | paid | THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $2,500,000 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | University of Iowa Iowa City, IA | U | $2,470,869 | paid | SIMULATION IN MOTION IOWA (SIM-IA) | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,451,335 | approved, future | CONTINUATION OF THE GPPAD-02-STUDY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,451,335 | approved, future | CONTINUATION OF THE GPPAD-02-STUDY | 202300389349100520 |
| 2022 | National Park Foundation Washington, DC | B | $2,449,328 | approved, future | BERING LAND BRIDGE VISITOR CENTER | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,440,023 | approved, future | CONTINUATION OF THE GPPAD-02-STUDY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,428,367 | approved, future | CONTINUATION OF THE GPPAD-02-STUDY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,428,367 | paid | CONTINUATION OF THE GPPAD-02-STUDY | 202300389349100520 |
| 2022 | The Sderot Development Foundation Sderot | U | $2,421,222 | approved, future | ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT | 202300389349100520 |
| 2022 | Sos Children's Villages-USA Inc Washington, DC | C | $2,401,776 | paid | EDUCARE 4.0: DEBRE TABOR AND GONDAR CITY, ETHIOPIA | 202300389349100520 |
| 2022 | Albert Einstein College of Medicine Bronx, NY | B | $2,381,358 | paid | PRECLINICAL WORK TO ADVANCE D-PEPTIDES AS ANTIGEN-SPECIFIC IMMUNOTHERAPY | 202300389349100520 |
| 2022 | Safe Water Network New York, NY | B | $2,367,100 | paid | SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,350,161 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | The Baruch Padeh Medical Center Poriya Tiberias | U | $2,321,666 | paid | CONSTRUCTION OF THE 12-BED INTENSIVE CARE AND RESPIRATION UNIT | 202300389349100520 |
| 2022 | Fund for Public Health in New York Inc New York, NY | B | $2,249,533 | paid | NYC VACCINE EQUITY PARTNER ENGAGEMENT PROJECT | 202300389349100520 |
| 2022 | Nevada Community Foundation Inc Las Vegas, NV | C | $2,216,426 | paid | DESERT VIEW AND MESA VIEW HOSPITAL EQUIPMENT REVITALIZATION PROJECT | 202300389349100520 |
| 2022 | Galilee Medical Center Nahariya | U | $2,200,000 | approved, future | RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING | 202300389349100520 |
| 2022 | Galilee Medical Center Nahariya | U | $2,200,000 | approved, future | RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING | 202300389349100520 |
| 2022 | Wateraid America Inc New York, NY | B | $2,166,773 | approved, future | CREATING A NEW REALITY FOR WASH IN HEALTHCARE FACILITIES IN ZAMBIA | 202300389349100520 |
| 2022 | Washoe Barton Medical Clinic Gardnerville, NV | D | $2,160,914 | paid | RADIOLOGY AND INTERVENTIONAL EQUIPMENT WITH CONSTRUCTION RELATED COSTS. | 202300389349100520 |
| 2022 | Indiana University (ampath Project) Indianapolis, IN | D | $2,131,500 | paid | AMPATH MODEL REPLICATION IN GHANA | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $2,075,000 | paid | PET/CT SCANNER FOR EMEK MEDICAL CENTER IN AFULA, ISRAEL | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $2,058,214 | approved, future | YOSEFTAL HOSPITAL ADDITION | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $2,045,026 | paid | BOUSSOUMA AND ZIGA, BURKINA FASO IMPROVED WASH INFRASTRUCTURE & SERVICES | 202300389349100520 |
| 2022 | Children's Mercy Hospital Kansas City, MO | B | $2,012,361 | paid | TYPE 1 DIABETES RAPID LEARNING LAB | 202300389349100520 |
| 2022 | Path Seattle, WA | C | $2,004,478 | approved, future | THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE | 202300389349100520 |
| 2022 | The One Love Foundation in Honor of Yeardley Love Inc Bronxville, NY | U | $2,000,000 | paid | BUILDING FOR THE FUTURE: SUPPORT FOR DIGITAL PROGRAMS AND OPERATIONS | 202300389349100520 |
| 2022 | The United Nations Institute for Training and Research Geneva | U | $2,000,000 | paid | ACCELERATING ACCESS: TREATMENT FOR NCDS IN LOW /MIDDLE-INCOME COUNTRIES. | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,988,392 | approved, future | PEN-PLUS EXPANSION | 202300389349100520 |
| 2022 | Schwartzreisman Science Education Center Rehovot Rehovot | U | $1,982,305 | approved, future | THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT | 202300389349100520 |
| 2022 | Yitzhak Shamir Medical Center Tzrifin | U | $1,978,286 | approved, future | EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE | 202300389349100520 |
| 2022 | Helen Keller International New York, NY | C | $1,941,293 | approved, future | A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,914,468 | approved, future | PEN-PLUS EXPANSION | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,914,468 | approved, future | PEN-PLUS EXPANSION | 202300389349100520 |
| 2022 | Helen Keller International New York, NY | C | $1,902,757 | paid | A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT | 202300389349100520 |
| 2022 | A Glimmer of Hope Foundation Austin, TX | C | $1,854,222 | approved, future | INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA | 202300389349100520 |
| 2022 | Central Montana Medical Facilities Inc Lewistown, MT | B | $1,840,000 | paid | CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER | 202300389349100520 |
| 2022 | Path Seattle, WA | C | $1,838,580 | approved, future | THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,829,719 | approved, future | GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,800,000 | paid | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | Incline Village Community Hospital Foundation Incline Village, NV | B | $1,796,260 | paid | DIAGNOSTIC IMAGING EQUIPMENT RELATED FUNDING SUPPORT | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,785,375 | approved, future | GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS | 202300389349100520 |
| 2022 | United States African Development Foundation Washington, DC | U | $1,779,762 | approved, future | LIVELIHOOD IMPROVEMENT PROGRAM | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $1,752,819 | paid | REDEFINING THE FUTURE OF EMERGENCY MEDICINE | 202300389349100520 |
| 2022 | National Park Foundation Washington, DC | B | $1,750,000 | approved, future | LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER | 202300389349100520 |
| 2022 | The Weizmann Institute of Science Rehovot | D | $1,750,000 | approved, future | THE QUANTUM MATERIALS DEVICES FABRICATION LAB | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $1,740,267 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | Blue Circle Health Inc Wilmington, DE | U | $1,740,266 | approved, future | CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D | 202300389349100520 |
| 2022 | The Weizmann Institute of Science Rehovot | D | $1,720,206 | approved, future | PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IN CROHNS | 202300389349100520 |
| 2022 | Water4 Inc Oklahoma City, OK | C | $1,673,164 | approved, future | SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER | 202300389349100520 |
| 2022 | New York City Health and Hospitals Corporation New York, NY | C | $1,657,500 | paid | EXPRESSCARE TELE-BEHAVIORAL SERV. & STRATEGIES (NYC HIGH NEEDS PATIENTS) | 202300389349100520 |
| 2022 | American Heart Association Inc Dallas, TX | B | $1,654,728 | approved, future | MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS | 202300389349100520 |
| 2022 | Helen Keller International New York, NY | C | $1,652,490 | approved, future | A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT | 202300389349100520 |
| 2022 | Health Finance Institute Arlington, VA | C | $1,633,848 | paid | CATALYZE FINANCE & PARTNERS TO ADDRESS GLOBAL BURDEN OF CHRONIC DISEASE | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,597,757 | paid | RURAL EMERGENCY HEALTH SERVICE AND TRANSPORT FOR SYSTEM DEVELOPMENT | 202300389349100520 |
| 2022 | Safe Water Network New York, NY | B | $1,595,750 | approved, future | SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY | 202300389349100520 |
| 2022 | Agricultural Research Organization Rishon Letsiyon | U | $1,591,900 | paid | THE HELMSLEY CENTER FOR AI IN AGRICULTURE AT THE VOLCANI CENTER | 202300389349100520 |
| 2022 | The Sderot Development Foundation Sderot | U | $1,558,573 | approved, future | SDEROT MEDICAL CENTER | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,556,214 | approved, future | INTEGRATED COMMUNITY WATER, SANITATION AND HYGIENE IMPROVEMENT IN GHANA | 202300389349100520 |
| 2022 | Safe Water Network New York, NY | B | $1,552,050 | approved, future | SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY | 202300389349100520 |
| 2022 | Baptist Medical Centre Nalerigu | U | $1,513,500 | paid | EMERGENCY CENTRE AND DOCTOR HOUSING DEVELOPMENT | 202300389349100520 |
| 2022 | King's College London London | U | $1,509,981 | paid | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | Global Solidarity Fund New York, NY | D | $1,508,200 | approved, future | JOB CREATION IN ETHIOPIA | 202300389349100520 |
| 2022 | Global Solidarity Fund New York, NY | D | $1,508,200 | approved, future | JOB CREATION IN ETHIOPIA | 202300389349100520 |
| 2022 | Global Solidarity Fund New York, NY | D | $1,508,200 | paid | JOB CREATION IN ETHIOPIA | 202300389349100520 |
| 2022 | Ziv Medical Center Zefat Zefat | U | $1,503,124 | paid | REINFORCE CRUCIAL SITES DURING EMERGENCIES: ORS, BLOOD BANK & PHARMACY | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $1,500,000 | approved, future | NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $1,500,000 | approved, future | NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $1,500,000 | approved, future | NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE | 202300389349100520 |
| 2022 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $1,500,000 | approved, future | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202300389349100520 |
| 2022 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $1,500,000 | approved, future | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $1,500,000 | approved, future | NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE | 202300389349100520 |
| 2022 | National Park Foundation Washington, DC | B | $1,500,000 | approved, future | BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER | 202300389349100520 |
| 2022 | Synergos Institute Inc New York, NY | B | $1,485,316 | paid | IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,482,901 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,482,900 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | New Venture Fund Washington, DC | B | $1,468,813 | approved, future | TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024) | 202300389349100520 |
| 2022 | Washoe Barton Medical Clinic Gardnerville, NV | D | $1,465,248 | approved, future | RADIOLOGY AND INTERVENTIONAL EQUIPMENT WITH CONSTRUCTION RELATED COSTS. | 202300389349100520 |
| 2022 | New York City Health and Hospitals Corporation New York, NY | C | $1,457,500 | approved, future | EXPRESSCARE TELE-BEHAVIORAL SERV. & STRATEGIES (NYC HIGH NEEDS PATIENTS) | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,454,620 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,454,619 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Henry J Kaiser Family Foundation San Francisco, CA | B | $1,451,938 | paid | KHN RURAL HEALTH DESK | 202300389349100520 |
| 2022 | A Glimmer of Hope Foundation Austin, TX | C | $1,449,415 | paid | INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA | 202300389349100520 |
| 2022 | Water4 Inc Oklahoma City, OK | C | $1,439,503 | approved, future | SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER | 202300389349100520 |
| 2022 | New Venture Fund Washington, DC | B | $1,435,500 | approved, future | TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024) | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,431,241 | approved, future | IDENTIFICATION OF INFANTS WITH HIGH RISK OF T1D - PRIMARY PREVENTION | 202300389349100520 |
| 2022 | Southcentral Foundation Anchorage, AK | B | $1,425,805 | paid | FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM | 202300389349100520 |
| 2022 | The Sderot Development Foundation Sderot | U | $1,422,851 | paid | ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $1,421,241 | approved, future | DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES | 202300389349100520 |
| 2022 | The Regents of the University of New Mexico Albuquerque, NM | U | $1,413,438 | paid | THE ECHO INSTITUTE: REPLICATION OF THE ECHO MODEL | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,410,856 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,410,856 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $1,405,714 | paid | KIRYAT SHMONA MEDICAL CLINIC | 202300389349100520 |
| 2022 | Path Seattle, WA | C | $1,404,393 | paid | THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE | 202300389349100520 |
| 2022 | National Park Foundation Washington, DC | B | $1,400,000 | approved, future | LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER | 202300389349100520 |
| 2022 | Children's Mercy Hospital Kansas City, MO | B | $1,399,624 | approved, future | TYPE 1 DIABETES RAPID LEARNING LAB | 202300389349100520 |
| 2022 | Sos Children's Villages-USA Inc Washington, DC | C | $1,386,577 | approved, future | EDUCARE 4.0: DEBRE TABOR AND GONDAR CITY, ETHIOPIA | 202300389349100520 |
| 2022 | Yad Sarah Jerusalem | D | $1,376,648 | paid | HOME HOSPITAL PROGRAM FOR SOUTHERN ISRAEL | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $1,374,460 | approved, future | DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $1,374,444 | approved, future | DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D | 202300389349100520 |
| 2022 | Clinton Health Access Initiative Inc Boston, MA | B | $1,372,583 | approved, future | MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE | 202300389349100520 |
| 2022 | Living Water International Stafford, CT | U | $1,369,113 | approved, future | INTEGRATED WASH PROGRAM IN CHIPATA DISTRICT, ZAMBIA | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $1,366,476 | paid | DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $1,355,310 | approved, future | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | American Heart Association Inc Dallas, TX | B | $1,346,286 | paid | AMERICAN BOARD OF TELEHEALTH PROGRAM EXPANSION | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,344,542 | approved, future | RURAL EMERGENCY HEALTH SERVICE AND TRANSPORT FOR SYSTEM DEVELOPMENT | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,339,873 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,339,873 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Mat-Su Trails & Parks Foundation Palmer, AK | B | $1,339,417 | paid | INDEPENDENCE MINE REHABILITATION | 202300389349100520 |
| 2022 | University of Pittsburgh Pittsburgh, PA | B | $1,338,570 | approved, future | RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN | 202300389349100520 |
| 2022 | National Committee for Quality Assurance Washington, DC | B | $1,336,294 | paid | TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, & ACCOUNTABILITY | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $1,335,936 | approved, future | CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS | 202300389349100520 |
| 2022 | Nevada Department of Health and Human Services Carson City, NV | U | $1,333,324 | approved, future | NEVADA VIRTUAL CRISIS CARE | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,326,053 | approved, future | INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,325,594 | paid | PEN-PLUS EXPANSION | 202300389349100520 |
| 2022 | King's College London London | U | $1,325,562 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $1,321,210 | approved, future | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Oregon Health & Science University Portland, OR | U | $1,316,877 | paid | TO EXPAND THE NICH PROGRAM IN THE CALIFORNIA BAY AREA | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $1,308,107 | approved, future | GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,301,918 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,301,917 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | The End Fund Inc New York, NY | B | $1,300,001 | paid | ELIMINATION OF PARASITIC WORMS IN ETHIOPIA | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $1,296,918 | approved, future | MINNESOTA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $1,296,812 | approved, future | EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $1,296,812 | paid | EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT | 202300389349100520 |
| 2022 | King's College London London | U | $1,296,483 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | Stichting Health Action International Amsterdam | U | $1,287,681 | approved, future | ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLLY | 202300389349100520 |
| 2022 | United States African Development Foundation Washington, DC | U | $1,283,255 | approved, future | LIVELIHOOD IMPROVEMENT PROGRAM | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,277,602 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,277,602 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Henry J Kaiser Family Foundation San Francisco, CA | B | $1,275,901 | approved, future | KHN RURAL HEALTH DESK | 202300389349100520 |
| 2022 | Living Water International Stafford, TX | B | $1,251,684 | paid | INTEGRATED WASH PROGRAM IN CHIPATA DISTRICT, ZAMBIA | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $1,250,000 | paid | JDRF TRAINING PROGRAMS | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $1,249,403 | approved, future | VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON | 202300389349100520 |
| 2022 | Stichting Health Action International Amsterdam | U | $1,246,224 | paid | ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLLY | 202300389349100520 |
| 2022 | Stichting Health Action International Amsterdam | U | $1,245,075 | approved, future | ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLLY | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $1,242,522 | paid | DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES | 202300389349100520 |
| 2022 | Henry J Kaiser Family Foundation San Francisco, CA | B | $1,239,878 | approved, future | KHN RURAL HEALTH DESK | 202300389349100520 |
| 2022 | Nevada Department of Health and Human Services Carson City, NV | U | $1,239,092 | approved, future | NEVADA VIRTUAL CRISIS CARE | 202300389349100520 |
| 2022 | The University of Queensland Brisbane | D | $1,231,993 | paid | LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET T1D | 202300389349100520 |
| 2022 | Nevada Department of Health and Human Services Carson City, NV | U | $1,230,038 | approved, future | NEVADA VIRTUAL CRISIS CARE | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $1,226,580 | approved, future | VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON | 202300389349100520 |
| 2022 | Seattle Children's Hospital Seattle, WA | U | $1,224,949 | approved, future | DEVELOPMENT OF ANTIGEN-SPECIFIC ETREG THERAPY IN T1D - STAGE 3 STUDIES | 202300389349100520 |
| 2022 | Snv Netherlands Development Organisation Den Haag | U | $1,207,754 | approved, future | HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE & NUTRITION | 202300389349100520 |
| 2022 | Salvation Army World Service Office Alexandria, VA | C | $1,200,000 | paid | WATER SYSTEM IMPROVEMENTS AT CHIKANKATA MISSION | 202300389349100520 |
| 2022 | University of Florida Gainesville, FL | U | $1,199,692 | approved, future | COLLABORATIVE T1D RESEARCH: NETWORK FOR PANCREATIC ORGAN DONORS WITH T1D | 202300389349100520 |
| 2022 | University of Florida Gainesville, FL | U | $1,199,692 | paid | COLLABORATIVE T1D RESEARCH: NETWORK FOR PANCREATIC ORGAN DONORS WITH T1D | 202300389349100520 |
| 2022 | Snv Netherlands Development Organisation Den Haag | U | $1,191,913 | paid | HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE & NUTRITION | 202300389349100520 |
| 2022 | The Regents of the University of New Mexico Albuquerque, NM | U | $1,188,238 | approved, future | THE ECHO INSTITUTE: REPLICATION OF THE ECHO MODEL | 202300389349100520 |
| 2022 | University of Pittsburgh Pittsburgh, PA | B | $1,184,954 | paid | RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN | 202300389349100520 |
| 2022 | Water4 Inc Oklahoma City, OK | C | $1,180,873 | paid | SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER | 202300389349100520 |
| 2022 | Joslin Diabetes Center Inc Boston, MA | B | $1,177,265 | paid | AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $1,173,337 | approved, future | DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM | 202300389349100520 |
| 2022 | Panorama Global Seattle, WA | B | $1,167,087 | approved, future | TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND | 202300389349100520 |
| 2022 | National Park Foundation Washington, DC | B | $1,163,270 | approved, future | BERING LAND BRIDGE VISITOR CENTER | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $1,162,617 | paid | DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $1,155,528 | paid | VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $1,153,809 | approved, future | DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM | 202300389349100520 |
| 2022 | American Heart Association Inc Dallas, TX | B | $1,144,990 | paid | MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS | 202300389349100520 |
| 2022 | King's College London London | U | $1,142,151 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | Jdrf Australia Sydney | U | $1,133,601 | paid | ENDIA FOLLOW UP 2020-2022 | 202300389349100520 |
| 2022 | Clinton Health Access Initiative Inc Boston, MA | B | $1,132,215 | approved, future | MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $1,118,393 | paid | KIRYAT SHMONA MEDICAL CLINIC | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,113,823 | paid | SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,111,050 | approved, future | CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,100,098 | approved, future | MAYI MWANA PROJECT: HELPING ZAMBIAN MOTHERS & NEWBORNS SURVIVE & THRIVE | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $1,093,319 | approved, future | DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES | 202300389349100520 |
| 2022 | King's College London London | U | $1,079,926 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | King's College London London | U | $1,074,992 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $1,067,400 | paid | SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH. | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $1,067,400 | approved, future | SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH. | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $1,067,400 | approved, future | SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH. | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,066,649 | paid | MAYI MWANA PROJECT: HELPING ZAMBIAN MOTHERS & NEWBORNS SURVIVE & THRIVE | 202300389349100520 |
| 2022 | Synergos Institute Inc New York, NY | B | $1,063,518 | approved, future | IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS | 202300389349100520 |
| 2022 | Ncd Alliance Geneva | U | $1,055,700 | paid | PUTTING PEOPLE WITH NCDS FIRST: DRIVING ADVOCACY, CHANGE, IMPROVING CARE | 202300389349100520 |
| 2022 | Floresta USA Incorporated San Diego, CA | C | $1,048,129 | paid | SCALING AT THE WATERSHED LEVEL TO EQUIP RURAL FAMILIES | 202300389349100520 |
| 2022 | New York University New York, NY | B | $1,046,686 | approved, future | IDENTIFYING ENVIRONMENTAL CONTRIBUTORS TO CROHNS DISEASE | 202300389349100520 |
| 2022 | University of Florida Gainesville, FL | U | $1,043,638 | approved, future | HUMAN ATLAS NEONATAL DEVELOPMENTAL EARLY LIFE PANCREAS/IMMUNITY CON'T | 202300389349100520 |
| 2022 | De la Salle Solidarietainternazionale Onlus Rome | U | $1,043,204 | paid | ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY | 202300389349100520 |
| 2022 | Nevada Community Foundation Inc Las Vegas, NV | C | $1,035,951 | approved, future | RURAL NEVADA ULTRASOUND CARE INITIATIVE | 202300389349100520 |
| 2022 | American Heart Association Inc Dallas, TX | B | $1,034,941 | paid | MISSION: LIFELINE STROKE SYSTEM OF CARE IN NEBRASKA | 202300389349100520 |
| 2022 | University of Florida Gainesville, FL | U | $1,034,449 | paid | HUMAN ATLAS NEONATAL DEVELOPMENTAL EARLY LIFE PANCREAS/IMMUNITY CON'T | 202300389349100520 |
| 2022 | The One Love Foundation in Honor of Yeardley Love Inc Bronxville, NY | U | $1,023,100 | approved, future | BUILDING FOR THE FUTURE: SUPPORT FOR DIGITAL PROGRAMS AND OPERATIONS | 202300389349100520 |
| 2022 | Ncd Alliance Geneva | U | $1,015,450 | paid | PUTTING PEOPLE WITH NCDS FIRST: DRIVING ADVOCACY, CHANGE, IMPROVING CARE | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $1,009,535 | approved, future | DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $1,009,155 | approved, future | MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,008,526 | approved, future | CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION | 202300389349100520 |
| 2022 | Billings Clinic Foundation Billings, MT | C | $1,000,000 | approved, future | MONTANA PSYCHIATRY RESIDENCY PROGRAM SUSTAINING SUPPORT | 202300389349100520 |
| 2022 | Yehuda Abarbanel Government Hospital Bat Yam | U | $1,000,000 | paid | MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS | 202300389349100520 |
| 2022 | The United Nations Institute for Training and Research Geneva | U | $1,000,000 | approved, future | ACCELERATING ACCESS: TREATMENT FOR NCDS IN LOW /MIDDLE-INCOME COUNTRIES. | 202300389349100520 |
| 2022 | Billings Clinic Foundation Billings, MT | C | $1,000,000 | paid | MONTANA PSYCHIATRY RESIDENCY PROGRAM SUSTAINING SUPPORT | 202300389349100520 |
| 2022 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $1,000,000 | approved, future | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202300389349100520 |
| 2022 | University of Iowa Iowa City, IA | U | $999,877 | approved, future | SIMULATION IN MOTION IOWA (SIM-IA) | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $999,800 | paid | JDRF GLOBAL DIABETES ACCESS INITIATIVE | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $999,800 | approved, future | JDRF GLOBAL DIABETES ACCESS INITIATIVE | 202300389349100520 |
| 2022 | Panorama Global Seattle, WA | B | $999,473 | approved, future | TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND | 202300389349100520 |
| 2022 | University of Pittsburgh Pittsburgh, PA | B | $998,931 | approved, future | RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN | 202300389349100520 |
| 2022 | Synergos Institute Inc New York, NY | B | $998,553 | paid | IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS | 202300389349100520 |
| 2022 | The Aspen Institute Inc Washington, DC | B | $998,081 | approved, future | THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION | 202300389349100520 |
| 2022 | The Aspen Institute Inc Washington, DC | B | $996,251 | approved, future | THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION | 202300389349100520 |
| 2022 | The Aspen Institute Inc Washington, DC | B | $995,988 | paid | THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $990,845 | paid | MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $976,541 | paid | LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION | 202300389349100520 |
| 2022 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $966,865 | approved, future | MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS | 202300389349100520 |
| 2022 | Snv Netherlands Development Organisation Den Haag | U | $962,857 | approved, future | HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE & NUTRITION | 202300389349100520 |
| 2022 | White Pine County Hospital District Ely, NV | U | $958,500 | paid | RADIOLOGY EQUIPMENT FOR HOSPITAL | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $954,604 | approved, future | CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS | 202300389349100520 |
| 2022 | Georgia Tech Research Corporation Atlanta, GA | C | $951,960 | paid | TRACKING & INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS | 202300389349100520 |
| 2022 | Alimentiv Inc London | U | $948,511 | approved, future | STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM | 202300389349100520 |
| 2022 | Amc Medical Research Bv Amsterdam | U | $942,690 | paid | IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE | 202300389349100520 |
| 2022 | International Water Management Institute Battaramulla | D | $942,226 | paid | WATER SECURE AFRICA INITIATIVE: OPEN DATA CUBE EXTENSION | 202300389349100520 |
| 2022 | Joslin Diabetes Center Inc Boston, MA | B | $941,354 | approved, future | AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES | 202300389349100520 |
| 2022 | Americares Foundation Inc Stamford, CT | C | $930,374 | paid | MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $926,084 | approved, future | CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $926,084 | approved, future | CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM | 202300389349100520 |
| 2022 | President and Fellows of Harvard College Boston, MA | C | $924,309 | paid | CREATING MICRONEEDLE-BASED SENSOR TO ENHANCE AUTOMATED INSULIN DELIVERY | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $905,046 | approved, future | SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS | 202300389349100520 |
| 2022 | Southcentral Foundation Anchorage, AK | B | $903,283 | approved, future | FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM | 202300389349100520 |
| 2022 | Wateraid America Inc New York, NY | B | $900,001 | paid | SYSTEM STRENGTHENING FOR SUSTAINABLE WASH SERVICES | 202300389349100520 |
| 2022 | Wyoming State Parks and Cultural Resources Cheyenne, WY | U | $885,000 | paid | INTERPRETIVE CENTER AT FORT PHIL KEARNY STATE HISTORIC SITE | 202300389349100520 |
| 2022 | Maccabi Healthcare Services Tel Aviv | U | $877,000 | paid | MOBILE MAMMOGRAPHY UNIT | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $875,045 | paid | PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13 | 202300389349100520 |
| 2022 | Guardian Org Foundation Washington, DC | B | $875,000 | paid | AN INDEPENDENT JOURNALISM SERIES ON NON-COMMUNICABLE DISEASES | 202300389349100520 |
| 2022 | Stichting Access to Medicine Foundation Amsterdam | U | $875,000 | approved, future | EXPANDING ACCESS TO T1D CARE | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $872,027 | paid | INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $870,315 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $870,314 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | United States Fund for Unicef New York, NY | U | $869,232 | approved, future | ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS | 202300389349100520 |
| 2022 | Joslin Diabetes Center Inc Boston, MA | B | $857,270 | approved, future | AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES | 202300389349100520 |
| 2022 | Association of Diabetes Care & Education Specialists Chicago, IL | B | $855,546 | approved, future | EXPANSION OF DANATECH PLATFORM | 202300389349100520 |
| 2022 | The Regents of the University of California at Irvine Irvine, CA | C | $851,633 | approved, future | DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D | 202300389349100520 |
| 2022 | Mainehealth Portland, ME | U | $848,894 | approved, future | TRANSFORMING RURAL DIABETES CARE IN MAINE | 202300389349100520 |
| 2022 | National Park Foundation Washington, DC | B | $848,202 | paid | BERING LAND BRIDGE VISITOR CENTER | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $847,748 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $847,748 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | Clinton Health Access Initiative Inc Boston, MA | B | $845,202 | paid | MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE | 202300389349100520 |
| 2022 | Massachusetts General Hospital Boston, MA | C | $843,986 | approved, future | DEVELOP A DEVICE TO IMPROVE ROUTINE DISEASE MONITORING FOR CD. | 202300389349100520 |
| 2022 | The Regents of the University of California at Irvine Irvine, CA | C | $837,543 | approved, future | DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D | 202300389349100520 |
| 2022 | The Regents of the University of California at Irvine Irvine, CA | C | $837,542 | approved, future | DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $836,979 | approved, future | INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE | 202300389349100520 |
| 2022 | National Committee for Quality Assurance Washington, DC | B | $836,732 | approved, future | TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, & ACCOUNTABILITY | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $833,493 | paid | DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D | 202300389349100520 |
| 2022 | Panorama Global Seattle, WA | B | $833,440 | paid | TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND | 202300389349100520 |
| 2022 | Association of Diabetes Care & Education Specialists Chicago, IL | B | $831,327 | approved, future | EXPANSION OF DANATECH PLATFORM | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $830,769 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $830,769 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $825,315 | paid | PANCREATLAS DATABASE EXPANSION. | 202300389349100520 |
| 2022 | New York City Health and Hospitals Corporation New York, NY | C | $825,000 | approved, future | EXPRESSCARE TELE-BEHAVIORAL SERV. & STRATEGIES (NYC HIGH NEEDS PATIENTS) | 202300389349100520 |
| 2022 | Southcentral Foundation Anchorage, AK | B | $818,171 | approved, future | FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $817,475 | approved, future | DIABETESWISE-PRO: INCREASING DIABETES DEVICE UPTAKE IN PEOPLE DIABETES | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $808,555 | paid | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $807,155 | approved, future | SUPPORT FOR INNODIA HARVEST ACTIVITIES AT ACADEMIC CONSORTIUM MEMBERS. | 202300389349100520 |
| 2022 | Washington University St Louis, MO | C | $800,222 | paid | VACCINE SAFETY AND EFFICACY | 202300389349100520 |
| 2022 | The University of Adelaide Adelaide | U | $794,339 | approved, future | ENVIRONMENTAL DETERMINANTS OF ISLET AUTOIMMUNITY (ENDIA) STUDY | 202300389349100520 |
| 2022 | Trustees of Indiana University Bloomington, IN | U | $793,072 | paid | MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $792,845 | paid | SUPPORT FOR INNODIA HARVEST ACTIVITIES AT ACADEMIC CONSORTIUM MEMBERS. | 202300389349100520 |
| 2022 | Alaska Native Tribal Health Consortium Anchorage, AK | B | $792,660 | paid | TULUKSAK WATER AND WASTEWATER SYSTEM | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $791,105 | paid | EQUIPMENT PURCHASES FOR THE NEW RADIOTHERAPY CENTER | 202300389349100520 |
| 2022 | United States Fund for Unicef New York, NY | U | $784,421 | approved, future | ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS | 202300389349100520 |
| 2022 | International Bowel Ultrasound Group Ev Munster | U | $779,377 | approved, future | THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND | 202300389349100520 |
| 2022 | King's College London London | U | $778,535 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | Alyn Hospital - Rehabilitation Center for Children and Youth Jerusalem | U | $777,749 | paid | ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH | 202300389349100520 |
| 2022 | United States Fund for Unicef New York, NY | U | $775,779 | paid | ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS | 202300389349100520 |
| 2022 | Hebrew University of Jerusalem Jerusalem | D | $775,164 | paid | METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS | 202300389349100520 |
| 2022 | Grand Canyon University Phoenix, AZ | U | $766,986 | paid | DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR | 202300389349100520 |
| 2022 | Australasian Gastro Intestinal Research Foundation Ltd Fitzroy | U | $758,947 | paid | FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $758,929 | paid | INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE | 202300389349100520 |
| 2022 | National Committee for Quality Assurance Washington, DC | B | $753,478 | approved, future | TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, & ACCOUNTABILITY | 202300389349100520 |
| 2022 | Americares Foundation Inc Stamford, CT | C | $752,688 | approved, future | MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS | 202300389349100520 |
| 2022 | Massachusetts General Hospital Boston, MA | C | $752,326 | approved, future | DEVELOP A DEVICE TO IMPROVE ROUTINE DISEASE MONITORING FOR CD. | 202300389349100520 |
| 2022 | National Park Foundation Washington, DC | B | $750,000 | approved, future | BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER | 202300389349100520 |
| 2022 | Stichting Access to Medicine Foundation Amsterdam | U | $750,000 | approved, future | EXPANDING ACCESS TO T1D CARE | 202300389349100520 |
| 2022 | Parker Institute for Cancer Immunotherapy San Francisco, CA | B | $750,000 | paid | STUDYING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES. | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $750,000 | approved, future | JDRF TRAINING PROGRAMS | 202300389349100520 |
| 2022 | Americares Foundation Inc Stamford, CT | C | $749,599 | approved, future | MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS | 202300389349100520 |
| 2022 | Catholic Relief Services-Usccb Baltimore, MD | C | $749,145 | approved, future | BOUSSOUMA AND ZIGA, BURKINA FASO IMPROVED WASH INFRASTRUCTURE & SERVICES | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $748,810 | paid | BIO-MDT APPROACH TO PERSONALIZED TREATMENT OF POUCHITIS | 202300389349100520 |
| 2022 | University of Iowa Iowa City, IA | U | $748,244 | approved, future | SIMULATION IN MOTION IOWA (SIM-IA) | 202300389349100520 |
| 2022 | King's College London London | U | $740,062 | paid | IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Ichud Hatzalah Israel 1221 (ra) Jerusalem | U | $739,000 | approved, future | UNITED HATZALAH HUMANITARIAN MISSION FOR UKRAINE | 202300389349100520 |
| 2022 | University of Notre Dame du Lac Notre Dame, IN | U | $736,645 | paid | GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES | 202300389349100520 |
| 2022 | Mainehealth Portland, ME | U | $729,688 | paid | TRANSFORMING RURAL DIABETES CARE IN MAINE | 202300389349100520 |
| 2022 | Yitzhak Shamir Medical Center Tzrifin | U | $729,642 | paid | EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $725,157 | approved, future | DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $724,198 | approved, future | VIRTUAL DIABETES SPECIALTY CLINIC STUDY EVALUATING REMOTE INITIATION CGM | 202300389349100520 |
| 2022 | Care-for-Rare Foundation Munich | U | $721,252 | approved, future | VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $719,309 | paid | HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE | 202300389349100520 |
| 2022 | International Bowel Ultrasound Group Ev Munster | U | $718,578 | approved, future | THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND | 202300389349100520 |
| 2022 | Alyn Hospital - Rehabilitation Center for Children and Youth Jerusalem | U | $717,219 | approved, future | ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH | 202300389349100520 |
| 2022 | The University of Adelaide Adelaide | U | $710,992 | paid | ENVIRONMENTAL DETERMINANTS OF ISLET AUTOIMMUNITY (ENDIA) STUDY | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $708,833 | approved, future | MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $705,874 | approved, future | FEASIBILITY EVAL OF AID IN PRIMARY CARE AND THROUGH TELEHEALTH | 202300389349100520 |
| 2022 | University of Melbourne Victoria | D | $703,827 | approved, future | ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR | 202300389349100520 |
| 2022 | Vayu Health Portola Valley, CA | B | $700,486 | approved, future | VAYU FEASIBILITY PILOT | 202300389349100520 |
| 2022 | Trustees of Indiana University Bloomington, MI | U | $696,962 | approved, future | MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES | 202300389349100520 |
| 2022 | New York University New York, NY | B | $695,626 | paid | IDENTIFYING ENVIRONMENTAL CONTRIBUTORS TO CROHNS DISEASE | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $694,245 | approved, future | SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS | 202300389349100520 |
| 2022 | Alyn Hospital - Rehabilitation Center for Children and Youth Jerusalem | U | $694,034 | approved, future | ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH | 202300389349100520 |
| 2022 | International Bowel Ultrasound Group Ev Munster | U | $693,935 | paid | THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $692,740 | paid | BIOMARKERS OF INTESTINAL FIBROSIS IN SMALL BOWEL CROHNS DISEASE | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $690,953 | approved, future | INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE | 202300389349100520 |
| 2022 | American Heart Association Inc Dallas, TX | B | $690,948 | approved, future | MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS | 202300389349100520 |
| 2022 | Central Montana Medical Facilities Inc Lewistown, MT | B | $690,035 | approved, future | CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER | 202300389349100520 |
| 2022 | Children's Hospital Los Angeles Los Angeles, CA | U | $684,686 | approved, future | BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE | 202300389349100520 |
| 2022 | Children's Hospital Los Angeles Los Angeles, CA | U | $679,025 | approved, future | BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $676,092 | paid | COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS | 202300389349100520 |
| 2022 | Hebrew University of Jerusalem Jerusalem | D | $671,024 | approved, future | METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $668,907 | paid | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $668,906 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202300389349100520 |
| 2022 | Lincoln County Hospital District Caliente, NV | U | $666,782 | paid | GROVER C. DILS MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $666,492 | paid | "TASTY & HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE. | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $666,216 | approved, future | NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $665,654 | approved, future | NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $664,751 | paid | NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE | 202300389349100520 |
| 2022 | Boulder City Hospital Inc Boulder City, NV | B | $663,285 | paid | BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $662,214 | paid | NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS | 202300389349100520 |
| 2022 | Benaroya Research Institute at Virginia Mason Seattle, WA | B | $661,927 | approved, future | LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D | 202300389349100520 |
| 2022 | The Weizmann Institute of Science Rehovot | D | $660,000 | approved, future | THE QUANTUM MATERIALS DEVICES FABRICATION LAB | 202300389349100520 |
| 2022 | Klinikum Der Universitt Munchen Munchen | U | $659,714 | approved, future | FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $659,685 | approved, future | PANCREATLAS DATABASE EXPANSION. | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $656,542 | approved, future | COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD | 202300389349100520 |
| 2022 | Washington University St Louis, MO | C | $656,480 | approved, future | VACCINE SAFETY AND EFFICACY | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $656,092 | approved, future | COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS | 202300389349100520 |
| 2022 | Care-for-Rare Foundation Munich | U | $655,603 | approved, future | VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH | 202300389349100520 |
| 2022 | Oregon Health & Science University Portland, OR | U | $654,234 | approved, future | TO EXPAND THE NICH PROGRAM IN THE CALIFORNIA BAY AREA | 202300389349100520 |
| 2022 | University of Notre Dame du Lac Notre Dame, IN | U | $652,642 | approved, future | DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM | 202300389349100520 |
| 2022 | Klinikum Der Universitt Munchen Munchen | U | $649,424 | approved, future | FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Klinikum Der Ludwig-Maximilians-Universitt Munchen | U | $644,601 | approved, future | FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Care-for-Rare Foundation Munich | U | $643,036 | paid | VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH | 202300389349100520 |
| 2022 | Klinikum Der Ludwig-Maximilians-Universitt Munchen Munchen | U | $639,055 | paid | FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE | 202300389349100520 |
| 2022 | University of Miami Coral Gables, FL | U | $637,761 | paid | A HOLISTIC DIET INTERVENTION FOR PEOPLE WITH CROHNS DISEASE | 202300389349100520 |
| 2022 | The Academic College at Tel-Hai Upper Galilee | U | $634,900 | paid | HELMSLEY SCIENCE BUILDING FOR HEALTH, ENVIRONMENT, AND BIOTECH STUDIES | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $631,739 | paid | DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS | 202300389349100520 |
| 2022 | University at Buffalo Pediatric Associates P C Buffalo, NY | D | $627,429 | paid | TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS | 202300389349100520 |
| 2022 | The University of Oxford Oxford | U | $627,089 | paid | STUDY OF COVID-19 ANTIBODY RESPONSE UNDER SUSTAINED IMMUNE SUPPRESSION | 202300389349100520 |
| 2022 | Bipartisan Policy Center Inc Washington, DC | B | $625,293 | approved, future | STRENGTHENING HEALTH CARE DELIVERY AND SERVICES IN RURAL AMERICA | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $625,000 | approved, future | EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY | 202300389349100520 |
| 2022 | Stichting Access to Medicine Foundation Amsterdam | U | $625,000 | paid | EXPANDING ACCESS TO T1D CARE | 202300389349100520 |
| 2022 | Guardian Org Foundation Washington, DC | B | $625,000 | approved, future | AN INDEPENDENT JOURNALISM SERIES ON NON-COMMUNICABLE DISEASES | 202300389349100520 |
| 2022 | Villages of Hope Africa Society Mississauga | D | $622,818 | paid | ZAMBIA DEVELOPMENT: FOOD PRODUCTION, WATER SUPPLY, EDUCATION FACILITIES | 202300389349100520 |
| 2022 | Bipartisan Policy Center Inc Washington, DC | B | $622,488 | paid | STRENGTHENING HEALTH CARE DELIVERY AND SERVICES IN RURAL AMERICA | 202300389349100520 |
| 2022 | National Committee for Quality Assurance Washington, DC | B | $621,487 | approved, future | TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, ACCOUNTABILITY | 202300389349100520 |
| 2022 | The University of Adelaide Adelaide | U | $620,581 | paid | ENDIA EXPANDED SUPPORT | 202300389349100520 |
| 2022 | University of Exeter Exeter | U | $615,166 | paid | UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES | 202300389349100520 |
| 2022 | The Sderot Development Foundation Sderot | U | $614,379 | approved, future | SDEROT MEDICAL CENTER | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $613,632 | paid | PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS | 202300389349100520 |
| 2022 | Amc Medical Research Bv Amsterdam | U | $610,817 | approved, future | IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE | 202300389349100520 |
| 2022 | Klinikum Der Ludwig-Maximilians-Universitt Munich | U | $606,581 | approved, future | FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $604,654 | paid | GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH OUTCOMES IN CHILDREN | 202300389349100520 |
| 2022 | Sanford Research Sioux Fall, SD | C | $603,695 | paid | SANFORD PLEDGE: PHASES 1 AND 2 | 202300389349100520 |
| 2022 | University of California Los Angeles Los Angeles, CA | U | $601,142 | paid | GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D | 202300389349100520 |
| 2022 | Klinikum Der Ludwig-Maximilians-Universitt Muchen | U | $600,891 | approved, future | FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $600,000 | paid | EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY | 202300389349100520 |
| 2022 | Mainehealth Portland, ME | U | $596,795 | approved, future | TRANSFORMING RURAL DIABETES CARE IN MAINE | 202300389349100520 |
| 2022 | University of Notre Dame du Lac Notre Dame, IN | U | $593,043 | approved, future | DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM | 202300389349100520 |
| 2022 | The Regents of the University of California San Diego La Jolla, CA | C | $593,024 | paid | PERSONALIZING CROHNS DISEASE THERAPEUTICS THROUGH PHASE 0 HUMAN TRIALS | 202300389349100520 |
| 2022 | University of Nebraska Foundation Lincoln, NE | C | $592,963 | paid | MOBILE RURAL HEALTHCARE PROVIDER TRAINING | 202300389349100520 |
| 2022 | Vayu Health Portola Valley, CA | B | $591,068 | paid | VAYU FEASIBILITY PILOT | 202300389349100520 |
| 2022 | Vayu Health Portola Valley, CA | B | $591,068 | approved, future | VAYU FEASIBILITY PILOT | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $589,062 | paid | CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $589,062 | paid | CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $588,266 | approved, future | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $588,266 | approved, future | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD | 202300389349100520 |
| 2022 | Australasian Gastro Intestinal Research Foundation Fitzroy | U | $587,840 | approved, future | FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY | 202300389349100520 |
| 2022 | Australasian Gastro Intestinal Research Foundation Fitzroy | U | $587,840 | approved, future | FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY | 202300389349100520 |
| 2022 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $585,750 | paid | IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES | 202300389349100520 |
| 2022 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $585,750 | approved, future | IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $582,660 | paid | BIO-MDT APPROACH TO PERSONALIZED TREATMENT OF POUCHITIS | 202300389349100520 |
| 2022 | University of Nebraska Foundation Lincoln, NE | C | $582,072 | approved, future | MOBILE RURAL HEALTHCARE PROVIDER TRAINING | 202300389349100520 |
| 2022 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $581,625 | approved, future | IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES | 202300389349100520 |
| 2022 | University of Notre Dame du Lac Notre Dame, IN | U | $581,100 | paid | DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM | 202300389349100520 |
| 2022 | Benaroya Research Institute at Virginia Mason Seattle, WA | B | $581,045 | paid | LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $580,677 | paid | CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $580,677 | approved, future | CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION | 202300389349100520 |
| 2022 | University at Buffalo Pediatric Associates P C Buffalo, NY | D | $576,839 | approved, future | TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $575,810 | approved, future | ASK THE EXPERTS | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $573,271 | paid | CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $570,831 | approved, future | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $570,830 | approved, future | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD | 202300389349100520 |
| 2022 | Trustees of Indiana University Bloomington, IN | U | $569,823 | paid | COLLABORATIVE EFFORT TO VALIDATE MICRORNAS AS BIOMARKERS OF T1D | 202300389349100520 |
| 2022 | University of California Los Angeles Los Angeles, CA | U | $568,851 | approved, future | GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D | 202300389349100520 |
| 2022 | University of California Los Angeles Los Angeles, CA | U | $568,027 | approved, future | GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D | 202300389349100520 |
| 2022 | Benaroya Research Institute at Virginia Mason Seattle, WA | B | $567,763 | approved, future | LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $567,507 | paid | GLUCOSE-RESPONSIVE APPROACHES TO INSULIN AND GLUCAGON DELIVERY | 202300389349100520 |
| 2022 | University of Exeter Exeter | U | $566,086 | approved, future | UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $562,221 | approved, future | INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD | 202300389349100520 |
| 2022 | Cambridge University Hospitals Nhs Foundation Trust Cambridge | U | $561,004 | approved, future | UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS | 202300389349100520 |
| 2022 | Albert Einstein College of Medicine Bronx, NY | B | $556,499 | approved, future | PRECLINICAL WORK TO ADVANCE D-PEPTIDES AS ANTIGEN-SPECIFIC IMMUNOTHERAPY | 202300389349100520 |
| 2022 | The Hospital for Sick Children Toronto | U | $555,480 | approved, future | VEOIBD: PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $553,832 | approved, future | GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE | 202300389349100520 |
| 2022 | University of Melbourne Carlton | D | $552,076 | paid | ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR | 202300389349100520 |
| 2022 | Nuru International Washington, DC | B | $550,893 | paid | NURU ETHIOPIA: SUSTAINING IMPACT THROUGH 2021 AND BEYOND | 202300389349100520 |
| 2022 | Public Health Solutions New York, NY | B | $550,000 | paid | NEW YORK CITY FUND FOR YOUTH AND FAMILY HOMELESSNESS | 202300389349100520 |
| 2022 | The Hospital for Sick Children Toronto | U | $548,276 | approved, future | VEOIBD: PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $548,201 | paid | GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS | 202300389349100520 |
| 2022 | Baylor College of Medicine Houston, TX | B | $547,540 | approved, future | EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED & PROACTIVE T1D CARE | 202300389349100520 |
| 2022 | The University of Oxford Oxford | U | $546,306 | approved, future | PHARMACOLOGICAL MODULATION TO ADDRESS GLUCAGON SECRETION IN T1D | 202300389349100520 |
| 2022 | Nebraska Department of Health & Human Services Lincoln, NE | U | $545,083 | approved, future | NEBRASKA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $544,115 | paid | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $543,207 | approved, future | ASK THE EXPERTS | 202300389349100520 |
| 2022 | University of Notre Dame du Lac Notre Dame, IN | U | $542,672 | approved, future | GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES | 202300389349100520 |
| 2022 | University of Massachusetts Medical School Worcester, MA | U | $541,529 | paid | DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS | 202300389349100520 |
| 2022 | Beth Israel Deaconess Medical Center Inc Boston, MA | B | $538,077 | approved, future | PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD | 202300389349100520 |
| 2022 | Beth Israel Deaconess Medical Center Inc Boston, MA | B | $538,077 | approved, future | PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD | 202300389349100520 |
| 2022 | City Parks Foundation New York, NY | B | $537,825 | paid | NYC GREEN RELIEF & RECOVERY FUND | 202300389349100520 |
| 2022 | University of California San Francisco San Francisco, CA | U | $537,711 | approved, future | ENGINEERING ISLET ANTIGEN-SPECIFIC TREGS FOR T1D | 202300389349100520 |
| 2022 | Baylor College of Medicine Houston, TX | B | $532,841 | approved, future | EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED PROACTIVE T1D CARE | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $530,355 | paid | AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $530,354 | approved, future | AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $527,468 | approved, future | "TASTY & HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE. | 202300389349100520 |
| 2022 | Children's Hospital Los Angeles Los Angeles, CA | U | $527,168 | paid | BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE | 202300389349100520 |
| 2022 | Beth Israel Deaconess Medical Center Inc Boston, MA | B | $526,637 | paid | PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD | 202300389349100520 |
| 2022 | Baylor College of Medicine Houston, TX | B | $524,854 | approved, future | PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $522,999 | approved, future | LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $522,458 | paid | ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $522,291 | approved, future | GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY | 202300389349100520 |
| 2022 | Beth Israel Deaconess Medical Center Inc Boston, MA | B | $519,550 | approved, future | PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD | 202300389349100520 |
| 2022 | Beth Israel Deaconess Medical Center Inc Boston, MA | B | $519,548 | approved, future | PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD | 202300389349100520 |
| 2022 | South Lyon Health Center Inc Yerington, NV | B | $518,553 | paid | SOUTH LYON MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT | 202300389349100520 |
| 2022 | Ballad Research Institute San Diego, CA | B | $516,369 | paid | CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS | 202300389349100520 |
| 2022 | Floresta USA Incorporated San Diego, CA | C | $516,231 | approved, future | SCALING AT THE WATERSHED LEVEL TO EQUIP RURAL FAMILIES | 202300389349100520 |
| 2022 | Oregon Health & Science University Portland, OR | U | $515,974 | paid | DESIGN AND EVALUATION OF A MDI DECISION SUPPORT SYSTEM | 202300389349100520 |
| 2022 | T1d Exchange Inc Boston, MA | U | $513,697 | paid | DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D | 202300389349100520 |
| 2022 | T1d Exchange Inc Boston, MA | U | $513,696 | paid | DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $512,661 | paid | CULTURALLY SENSITIVE GROUP CLINIC MODEL FOR LATINO PATIENTS W/ DIABETES | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $509,159 | paid | COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $507,558 | paid | ASK THE EXPERTS | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $506,838 | paid | MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $504,261 | paid | USE OF MRI OF THE PANCREAS IN T1D | 202300389349100520 |
| 2022 | University of Notre Dame du Lac Notre Dame, IN | U | $503,082 | approved, future | GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES | 202300389349100520 |
| 2022 | Villages of Hope Africa Society Mississauga | D | $502,010 | approved, future | ZAMBIA DEVELOPMENT: FOOD PRODUCTION, WATER SUPPLY, EDUCATION FACILITIES | 202300389349100520 |
| 2022 | Baylor College of Medicine Houston, TX | B | $501,482 | paid | PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE | 202300389349100520 |
| 2022 | Baylor College of Medicine Houston, TX | B | $500,994 | paid | EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED & PROACTIVE T1D CARE | 202300389349100520 |
| 2022 | Palo Alto Veterans Institute for Research Palo Alto, CA | B | $500,825 | paid | CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Palo Alto Veterans Institute for Research Palo Alto, CA | B | $500,825 | approved, future | CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Baylor College of Medicine Houston, TX | B | $500,180 | approved, future | PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE | 202300389349100520 |
| 2022 | University of California San Francisco San Francisco, CA | U | $500,120 | paid | ENGINEERING ISLET ANTIGEN-SPECIFIC TREGS FOR T1D | 202300389349100520 |
| 2022 | University of Cambridge Cambridge | U | $500,000 | approved, future | CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2 | 202300389349100520 |
| 2022 | Ichud Hatzalah Israel 1221 (ra) Jerusalem | U | $500,000 | paid | URGENT NEED FOR PROTECTIVE VESTS AND HELMETS | 202300389349100520 |
| 2022 | Platte Valley Healthcare Project Saratoga, WY | B | $500,000 | paid | CT SCANNER AT NORTH PLATTE VALLEY MEDICAL CENTER | 202300389349100520 |
| 2022 | The Jewish Agency for Israel Jerusalem | D | $500,000 | paid | JEWISH REFUGEES/ALIYAH CANDIDATES FROM UKRAINE | 202300389349100520 |
| 2022 | Natural Areas Conservancy Inc New York, NY | B | $500,000 | paid | FORMALIZING A NEW YORK CITY TRAIL SYSTEM | 202300389349100520 |
| 2022 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $500,000 | paid | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202300389349100520 |
| 2022 | Nature Conservancy Arlington, VA | B | $500,000 | paid | FUTURE FOREST NEW YORK CITY PHASE II | 202300389349100520 |
| 2022 | Public Health Solutions New York, NY | B | $500,000 | paid | NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE | 202300389349100520 |
| 2022 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $500,000 | approved, future | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202300389349100520 |
| 2022 | Simulation in Motion Montana Inc Helena, MT | B | $500,000 | paid | CAPACITY BUILDING FOR A SUSTAINABLE SIMULATION IN MOTION MONTANA PROGRAM | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $499,459 | approved, future | INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD | 202300389349100520 |
| 2022 | Palo Alto Veterans Institute for Research Palo Alto, CA | B | $499,175 | paid | CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Palo Alto Veterans Institute for Research Palo Alto, CA | B | $499,175 | approved, future | CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $497,699 | paid | AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT | 202300389349100520 |
| 2022 | University of Cambridge Cambridge | U | $496,568 | approved, future | CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2 | 202300389349100520 |
| 2022 | Mayo Clinic Rochester, MN | U | $495,833 | paid | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $494,615 | paid | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $492,812 | paid | MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $492,017 | approved, future | MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE | 202300389349100520 |
| 2022 | City Parks Foundation New York, NY | B | $491,131 | approved, future | CATALYST: GROWING INTENSIVE PARK ENGAGEMENT IN VULNERABLE COMMUNITIES | 202300389349100520 |
| 2022 | The University of Chicago Chicago, IL | U | $487,806 | paid | A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE | 202300389349100520 |
| 2022 | The University of Chicago Chicago, IL | U | $487,806 | approved, future | A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE | 202300389349100520 |
| 2022 | The University of Chicago Chicago, IL | U | $487,806 | paid | A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE | 202300389349100520 |
| 2022 | Georgia Tech Research Corporation Atlanta, GA | C | $485,617 | approved, future | TRACKING INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS | 202300389349100520 |
| 2022 | Georgia Tech Research Corporation Atlanta, GA | C | $485,616 | approved, future | TRACKING & INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $482,282 | paid | EVALUATING AID TECHNOLOGY IN PREGNANT WOMEN WITH T1D | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $481,994 | paid | INNODIA HARVEST | 202300389349100520 |
| 2022 | Tampere University Foundation Sr Tampere | U | $481,830 | paid | DEVELOPMENT OF MULTIPLEX MICROBIAL ANTIBODY SCREENING ARRAY FOR STUDIES | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $481,225 | paid | MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE | 202300389349100520 |
| 2022 | Georgia Tech Research Corporation Atlanta, GA | C | $480,848 | approved, future | TRACKING INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS | 202300389349100520 |
| 2022 | Georgia Tech Research Corporation Atlanta, GA | C | $480,848 | approved, future | TRACKING AND INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS | 202300389349100520 |
| 2022 | City Parks Foundation New York, NY | B | $479,444 | paid | CATALYST: GROWING INTENSIVE PARK ENGAGEMENT IN VULNERABLE COMMUNITIES | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $479,190 | paid | MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $476,319 | paid | HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE | 202300389349100520 |
| 2022 | Aphp St Antoine Hospital Paris | U | $474,464 | approved, future | FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Aphp St Antoine Hospital Paris | U | $474,464 | approved, future | FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $469,844 | paid | MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION | 202300389349100520 |
| 2022 | Forschergruppe Diabetes Ev Neuherberg | U | $467,844 | paid | FR1DA-PLUS COHORT STUDY | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $463,755 | approved, future | HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE | 202300389349100520 |
| 2022 | The Broad Institute Inc Cambridge, MA | B | $463,751 | approved, future | HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE | 202300389349100520 |
| 2022 | St Rose Dominican Health Foundation Henderson, NV | U | $462,090 | paid | MEDICAL SIMULATION EQUIPMENT | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $460,108 | approved, future | FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT | 202300389349100520 |
| 2022 | Yehuda Abarbanel Government Hospital Bat Yam | U | $454,960 | approved, future | MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS | 202300389349100520 |
| 2022 | Regents of the University of Mi Ann Arbor, MI | D | $454,441 | approved, future | HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $453,159 | paid | CGM MONITORING OF MATERNAL DYSGLYCEMIA | 202300389349100520 |
| 2022 | The Sheba Fund for Health Services and Research (ra) Ramat Gan | U | $452,624 | paid | COMPREHENSIVE INDIVIDUALIZED PROACTIVE THERAPY OF CROHNS DISEASE | 202300389349100520 |
| 2022 | University of Oulu Oulu | U | $452,607 | paid | MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $451,795 | paid | THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL & PREVENTION | 202300389349100520 |
| 2022 | Beyond Type 1 San Carlos, CA | D | $451,667 | paid | DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3 | 202300389349100520 |
| 2022 | University of Exeter Exeter | U | $451,469 | approved, future | UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES | 202300389349100520 |
| 2022 | Children's Mercy Hospital Kansas City, MO | B | $445,112 | paid | TYPE 1 DIABETES RAPID LEARNING LAB | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $444,247 | approved, future | GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $444,246 | approved, future | GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE | 202300389349100520 |
| 2022 | Yale University New Haven, CT | U | $443,827 | approved, future | EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE | 202300389349100520 |
| 2022 | Washoe Barton Medical Clinic Gardnerville, NV | D | $437,369 | paid | ULTRASOUND EQUIPMENT FOR CARSON VALLEY MEDICAL CENTER | 202300389349100520 |
| 2022 | The University of Queensland Brisbane | D | $435,713 | approved, future | LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET T1D | 202300389349100520 |
| 2022 | University of California San Francisco San Francisco, CA | U | $433,333 | paid | ID ANALYSIS OF EXTREME FORMS OF T1D, ESTABLISHMENT OF PATIENT REGISTRY | 202300389349100520 |
| 2022 | University of California San Francisco San Francisco, CA | U | $433,333 | approved, future | ID ANALYSIS OF EXTREME FORMS OF T1D, ESTABLISHMENT OF PATIENT REGISTRY | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $432,631 | paid | DEVELOPMENT OF NOVEL INSULIN INFUSION SET | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $430,508 | approved, future | IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN | 202300389349100520 |
| 2022 | Mi State University East Lansing, MI | U | $430,158 | paid | A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH T1D | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $429,646 | approved, future | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Trustees of Indiana University Bloomington, MI | U | $426,380 | approved, future | COLLABORATIVE EFFORT TO VALIDATE MICRORNAS AS BIOMARKERS OF T1D | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $425,771 | approved, future | CGM MONITORING OF MATERNAL DYSGLYCEMIA | 202300389349100520 |
| 2022 | Children's Hospital of Philadelphia Philadelphia, PA | C | $424,937 | paid | CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $423,667 | paid | IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN | 202300389349100520 |
| 2022 | Aphp St Antoine Hospital Paris | U | $421,681 | approved, future | FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE | 202300389349100520 |
| 2022 | The University of Adelaide Adelaide | U | $419,418 | approved, future | ENDIA EXPANDED SUPPORT | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $419,010 | approved, future | DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $415,688 | approved, future | NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $415,688 | approved, future | NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $415,669 | paid | "TASTY & HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE. | 202300389349100520 |
| 2022 | University of Birmingham Birmingham | U | $413,518 | paid | DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR T1D. | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $413,468 | paid | PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $413,263 | approved, future | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Association of Diabetes Care & Education Specialists Chicago, IL | B | $413,127 | approved, future | EXPANSION OF DANATECH PLATFORM | 202300389349100520 |
| 2022 | Regents of the University of Mi Ann Arbor, MI | D | $412,982 | paid | HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS | 202300389349100520 |
| 2022 | The Sonia Nabeta Foundation Inc New York, NY | C | $412,944 | approved, future | PROJECT BODA | 202300389349100520 |
| 2022 | The University of Chicago Chicago, IL | U | $411,939 | paid | IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $409,388 | approved, future | MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS | 202300389349100520 |
| 2022 | Regents of the University of Mi Ann Arbor, MI | D | $408,267 | approved, future | HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $408,046 | approved, future | COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD | 202300389349100520 |
| 2022 | Yale University New Haven, CT | U | $405,488 | paid | EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $404,688 | approved, future | NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $403,400 | paid | DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD | 202300389349100520 |
| 2022 | Pershing County Hospital District Lovelock, NV | U | $401,978 | paid | PERSHING GENERAL HOSPITAL EQUIPMENT REVITALIZATION PROJECT. | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $400,400 | paid | GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $400,000 | paid | AUTOIMMUNITY SCREENING IN KIDS (ASK) RENEWAL | 202300389349100520 |
| 2022 | Uppsala University Hospital Uppsala | U | $400,000 | paid | ISOLATING ISLETS TO UNDERSTAND ALPHA CELL DYSFUNCTION AND HYPOGLYCEMIA | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $400,000 | approved, future | EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY | 202300389349100520 |
| 2022 | Israel Antiquities Authority Jerusalem | U | $400,000 | approved, future | JAY & JEANIE SCHOTTENSTEIN NATIONAL CAMPUS FOR THE ARCHAEOLOGY OF ISRAEL | 202300389349100520 |
| 2022 | Association of Diabetes Care & Education Specialists Chicago, IL | B | $400,000 | paid | EXPANSION OF DANATECH PLATFORM | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $399,368 | approved, future | 2022-2024 TYPE 1 DIABETES CAMP INITIATIVE | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $399,368 | approved, future | 2022-2024 TYPE 1 DIABETES CAMP INITIATIVE | 202300389349100520 |
| 2022 | Herlev Og Gentofte Hospital Herlev | U | $394,362 | approved, future | TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $393,039 | paid | TARGETING MICROORGANISMS IN CREEPING FAT | 202300389349100520 |
| 2022 | University of Glasgow Court Glasgow | U | $391,290 | paid | THE CLINICAL EFFECTIVENESS OF CD-TREAT IN PATIENTS WITH ACTIVE CROHNS | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $387,943 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY | 202300389349100520 |
| 2022 | Mayo Clinic Rochester, MN | U | $385,906 | approved, future | OFF-SITE REMOTE CONTROL ROBOTIC PERCUTANEOUS CORONARY INTERVENTIONS | 202300389349100520 |
| 2022 | Regents of the University of Mi Ann Arbor, MI | D | $385,780 | approved, future | USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS. | 202300389349100520 |
| 2022 | Ichud Hatzalah Israel 1221 (ra) Jerusalem | U | $385,000 | paid | UNITED HATZALAH HUMANITARIAN MISSION FOR UKRAINE | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $384,845 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $382,893 | paid | ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024 | 202300389349100520 |
| 2022 | Mi State University East Lansing, MI | U | $382,594 | approved, future | A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH T1D | 202300389349100520 |
| 2022 | Regents of the University of Mi Ann Arbor, MI | D | $381,754 | paid | USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS. | 202300389349100520 |
| 2022 | University College London London | U | $380,649 | paid | SPIT-C: USING SALIVA TO PREDICT CROHNS DISEASE | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $379,439 | paid | PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK | 202300389349100520 |
| 2022 | United Nations Development Programme New York, NY | C | $377,955 | approved, future | UNITED NATIONS MULTILATERAL AGENCY | 202300389349100520 |
| 2022 | New Destiny Housing Corporation New York, NY | B | $376,970 | paid | AFTERCARE INTERVENTION TO IMPROVE HOUSING & HEALTH STABILITY | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $375,747 | paid | TARGETING MICROORGANISMS IN CREEPING FAT | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $375,235 | paid | SAFETY AND TOLERABILITY OF ORAL BFAHF-2 IN PEDIATRIC CROHNS DISEASE | 202300389349100520 |
| 2022 | International Bowel Ultrasound Group Ev Munster | U | $375,221 | approved, future | THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND | 202300389349100520 |
| 2022 | United Hospital Fund of New York New York, NY | B | $375,000 | paid | NEW YORK STATE MEDICAL RESPITE PILOT PROGRAM DESIGN | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $374,912 | approved, future | IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $374,591 | approved, future | MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $374,591 | approved, future | MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $374,591 | approved, future | MOLECULAR SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE | 202300389349100520 |
| 2022 | Children's Hospital Corporation Boston, MA | C | $374,591 | approved, future | MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE | 202300389349100520 |
| 2022 | Institut Nationale de la Sante de la Recherche Medicale Paris | U | $373,431 | paid | BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $373,041 | approved, future | USE OF MRI OF THE PANCREAS IN T1D | 202300389349100520 |
| 2022 | King's College London London | U | $369,984 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202300389349100520 |
| 2022 | Regents of the University of Mi Ann Arbor, MI | D | $369,880 | approved, future | USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS. | 202300389349100520 |
| 2022 | Aphp St Antoine Hospital Paris | U | $367,129 | approved, future | FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Alimentiv Inc London | U | $366,257 | paid | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $364,763 | approved, future | LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION | 202300389349100520 |
| 2022 | University of Cincinnati Cincinnati, OH | B | $363,107 | paid | UNDERSTANDING THE EFFECT OF C-PEPTIDE CO-INFUSION WITH INSULIN | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $362,770 | approved, future | COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD | 202300389349100520 |
| 2022 | Hebrew University of Jerusalem Jerusalem | D | $362,703 | approved, future | METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS | 202300389349100520 |
| 2022 | Children's Hospital Los Angeles Los Angeles, CA | U | $360,832 | paid | TEAM CLINIC: EXPANSION OF A CARE MODEL FOR ADOLESCENTS WITH T1D | 202300389349100520 |
| 2022 | Brigham and Women's Hospital Boston, MA | C | $360,771 | approved, future | PASSIVE WIRELESS MONITORING TO PREDICT AND TRACK CROHNS DISEASE | 202300389349100520 |
| 2022 | Johns Hopkins University Baltimore, MD | U | $360,255 | paid | A MULTIDISCIPLINARY BIOENGINEERING APPROACH TO FISTULA-IN-ANO IN CROHNS | 202300389349100520 |
| 2022 | Parker Institute for Cancer Immunotherapy San Francisco, CA | B | $358,140 | approved, future | STUDYING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES. | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $355,916 | approved, future | PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK | 202300389349100520 |
| 2022 | T1d Exchange Inc Boston, MA | U | $354,000 | paid | DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D | 202300389349100520 |
| 2022 | T1d Exchange Inc Boston, MA | U | $354,000 | paid | DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D | 202300389349100520 |
| 2022 | T1d Exchange Inc Boston, MA | U | $354,000 | paid | DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D | 202300389349100520 |
| 2022 | Massachusetts General Hospital Boston, MA | C | $353,249 | approved, future | CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION | 202300389349100520 |
| 2022 | University of Cambridge Cambridge | U | $353,223 | approved, future | CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2 | 202300389349100520 |
| 2022 | Massachusetts General Hospital Boston, MA | C | $352,645 | approved, future | CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $351,258 | approved, future | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Massachusetts General Hospital Boston, MA | C | $350,279 | paid | CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION | 202300389349100520 |
| 2022 | Massachusetts General Hospital Boston, MA | C | $350,278 | approved, future | CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $350,000 | paid | PHASE 2: ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR T1D | 202300389349100520 |
| 2022 | Rambam Health Corporation Haifa | D | $350,000 | paid | PREDICTING AND OPTIMIZING DRUG THERAPY IN CROHNS DISEASE | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $348,000 | approved, future | DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD | 202300389349100520 |
| 2022 | Insulin for Life USA Inc Gainesville, FL | B | $341,606 | approved, future | INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $339,811 | approved, future | EXERCISE EDUCATION AT NEW ONSET OF T1D | 202300389349100520 |
| 2022 | United Nations Development Programme New York, NY | C | $339,777 | approved, future | UNITED NATIONS MULTILATERAL AGENCY | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $337,310 | approved, future | ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024 | 202300389349100520 |
| 2022 | Yale University New Haven, CT | U | $336,846 | paid | THERAPEUTIC TARGETS AT THE HOST MICROBIOTA INTERFACE FOR FIBROSIS | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $334,798 | approved, future | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $334,722 | paid | EFFECTS OF AN INTERMITTENT REDUCED CALORIE DIET ON CROHNS DISEASE | 202300389349100520 |
| 2022 | Mayo Clinic Rochester, MN | U | $334,407 | approved, future | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Friends of the Israel Defense Forces New York, NY | B | $334,400 | approved, future | THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM | 202300389349100520 |
| 2022 | Friends of the Israel Defense Forces New York, NY | B | $334,400 | paid | THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM | 202300389349100520 |
| 2022 | Friends of the Israel Defense Forces New York, NY | B | $334,400 | approved, future | THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $331,803 | paid | EFFECTS OF AN INTERMITTENT REDUCED CALORIE DIET ON CROHNS DISEASE | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $331,671 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY | 202300389349100520 |
| 2022 | The Rector and Visitors of the University of Virginia Charlottesville, VA | C | $331,333 | approved, future | TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $331,219 | paid | 2022-2024 TYPE 1 DIABETES CAMP INITIATIVE | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $330,000 | approved, future | EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $330,000 | approved, future | IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $330,000 | paid | IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA | 202300389349100520 |
| 2022 | Townsend Health Systems Inc Townsend, MT | U | $329,602 | paid | TELE-PHARMACY AT BILLINGS CLINIC BROADWATER | 202300389349100520 |
| 2022 | University of Miami Coral Gables, FL | U | $328,238 | approved, future | THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE | 202300389349100520 |
| 2022 | University of Miami Coral Gables, FL | U | $326,055 | approved, future | THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE | 202300389349100520 |
| 2022 | Ballad Research Institute San Diego, CA | B | $325,801 | approved, future | CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $323,983 | paid | IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS | 202300389349100520 |
| 2022 | University of Miami Coral Gables, FL | U | $323,935 | paid | THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE | 202300389349100520 |
| 2022 | University of Exeter Exeter | U | $323,139 | approved, future | STIMULATED GLUCAGON LEVELS BIOMARKER OF HYPOGLYCEMIA RISK IN T1D | 202300389349100520 |
| 2022 | University of Birmingham Birmingham | U | $322,720 | approved, future | DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR T1D. | 202300389349100520 |
| 2022 | Insulin for Life USA Inc Gainesville, FL | B | $320,933 | approved, future | INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $315,009 | paid | RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE | 202300389349100520 |
| 2022 | The Sonia Nabeta Foundation Inc New York, NY | C | $314,814 | paid | PROJECT BODA | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $313,924 | paid | DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR | 202300389349100520 |
| 2022 | Cambridge University Hospitals Nhs Foundation Trust Cambridge | U | $313,576 | approved, future | UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS | 202300389349100520 |
| 2022 | Cambridge University Hospitals Nhs Foundation Trust Cambridge | U | $313,576 | approved, future | UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS | 202300389349100520 |
| 2022 | Cambridge University Hospitals Nhs Foundation Trust Cambridge | U | $312,018 | paid | UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS | 202300389349100520 |
| 2022 | University of Massachusetts Medical School Worcester, MA | U | $311,133 | approved, future | DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS | 202300389349100520 |
| 2022 | University of Massachusetts Medical School Worcester, MA | U | $311,131 | approved, future | DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS | 202300389349100520 |
| 2022 | Pulitzer Center On Crisis Reporting Washington, DC | C | $310,123 | approved, future | BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION | 202300389349100520 |
| 2022 | Nebraska Department of Health & Human Services Lincoln, NE | U | $309,887 | approved, future | NEBRASKA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $308,267 | approved, future | PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13 | 202300389349100520 |
| 2022 | King's College London London | U | $307,779 | approved, future | EVALUATE THE BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA | 202300389349100520 |
| 2022 | The Tel Aviv Jaffa Academic College Tel Aviv Yaffo | U | $306,724 | approved, future | SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES | 202300389349100520 |
| 2022 | Uppsala Universitet Uppsala | U | $305,920 | approved, future | ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION | 202300389349100520 |
| 2022 | The University of Chicago Chicago, IL | U | $305,353 | approved, future | IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $305,349 | approved, future | NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE | 202300389349100520 |
| 2022 | The University of Chicago Chicago, IL | U | $305,349 | paid | IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS | 202300389349100520 |
| 2022 | Tampere University Foundation Sr Tampere | U | $305,030 | paid | VIRUSES AND ANTIVIRAL IMMUNE MARKERS IN TWO ENDOTYPES OF TYPE 1 DIABETES | 202300389349100520 |
| 2022 | Pulitzer Center On Crisis Reporting Washington, DC | C | $302,170 | approved, future | BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION | 202300389349100520 |
| 2022 | United Hospital Fund of New York New York, NY | B | $300,000 | paid | NEW YORK STATE MEDICAL RESPITE PILOT PROGRAM DESIGN | 202300389349100520 |
| 2022 | Washington University St Louis, MO | C | $300,000 | paid | SUPPORT DRUG DISCOVERY/UNDERSTANDING AND PREVENTING HYPOGLYCEMIA IN T1D | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $300,000 | paid | FOCUS ON FELLOWS, DIABETES IS PRIMARY, PROFESSIONAL MEMBERSHIP PROJECTS | 202300389349100520 |
| 2022 | City Parks Foundation New York, NY | B | $300,000 | approved, future | NYC GREEN RELIEF & RECOVERY FUND | 202300389349100520 |
| 2022 | The Tel Aviv Jaffa Academic College Tel Aviv Yaffo | U | $300,000 | paid | SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $300,000 | approved, future | FOCUS ON FELLOWS, DIABETES IS PRIMARY, PROFESSIONAL MEMBERSHIP PROJECTS | 202300389349100520 |
| 2022 | Veterans Memorial Hospital Waukon, IA | D | $299,175 | paid | ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL | 202300389349100520 |
| 2022 | Yale University New Haven, CT | U | $298,606 | approved, future | EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $297,612 | approved, future | RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE | 202300389349100520 |
| 2022 | Insulin for Life USA Inc Gainesville, FL | B | $296,175 | paid | INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY | 202300389349100520 |
| 2022 | Universite Libre de Bruxelles Brussels | U | $295,566 | approved, future | DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS. | 202300389349100520 |
| 2022 | De la Salle Solidarietainternazionale Onlus Rome | U | $294,372 | paid | ESTABLISHING A ROBUST MEDICAL EDUCATION CENTER - ETHIOPIA | 202300389349100520 |
| 2022 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $293,370 | approved, future | ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD | 202300389349100520 |
| 2022 | University of Utah Salt Lake City, UT | B | $291,996 | paid | ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE | 202300389349100520 |
| 2022 | Trustees of Indiana University Bloomington, IN | U | $290,356 | paid | DEVELOPMENT OF REGULATORY ROADMAP FOR COLONOSCOPY BOWEL PREP FOR CD PTS | 202300389349100520 |
| 2022 | The Health & Housing Consortium Inc Bronx, NY | C | $290,000 | paid | STRATEGY BUILDING FOR HEALTH AND HOUSING CONSORTIUM EXPANSION | 202300389349100520 |
| 2022 | King's College London London | U | $288,101 | approved, future | IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $286,838 | approved, future | IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $286,747 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY | 202300389349100520 |
| 2022 | Hannoversche Kinderheilanstalt Hannover | U | $286,700 | paid | FR1DA IN NORTH GERMANY: PRE-SYMPTOMATIC TYPE 1 DIABETES TESTING IN KIDS | 202300389349100520 |
| 2022 | University of Massachusetts Medical School Worcester, MA | U | $286,614 | approved, future | DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS | 202300389349100520 |
| 2022 | University of Massachusetts Medical School Worcester, MA | U | $286,613 | approved, future | DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS | 202300389349100520 |
| 2022 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $285,463 | approved, future | ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD | 202300389349100520 |
| 2022 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $285,463 | approved, future | ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD | 202300389349100520 |
| 2022 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $285,079 | approved, future | ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $284,646 | approved, future | RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE | 202300389349100520 |
| 2022 | Healthpartners Institute Minneapolis, MN | B | $284,446 | paid | DIRECT INTEGRATION OF CGM DATA INTO THE EMR | 202300389349100520 |
| 2022 | University of Oulu Oulu | U | $284,289 | approved, future | MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING | 202300389349100520 |
| 2022 | Medical College of Cornell University New York, NY | U | $283,903 | paid | TARGETING THE MYCOBIOME IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $283,542 | approved, future | EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $282,554 | approved, future | BIOMARKERS OF INTESTINAL FIBROSIS IN SMALL BOWEL CROHNS DISEASE | 202300389349100520 |
| 2022 | Children's Hospital of Philadelphia Philadelphia, PA | C | $281,734 | paid | CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $278,350 | approved, future | ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024 | 202300389349100520 |
| 2022 | Project Nyame Nsa Ltd Manhasset, NY | U | $277,650 | paid | PROJECT NYAME NSA ZAMBIA EXPANSION | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $275,688 | approved, future | IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $275,588 | approved, future | IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS | 202300389349100520 |
| 2022 | The City of Hope Duarte, CA | U | $275,000 | paid | UNDERSTANDING GENETIC PROTECTION FROM T1D. | 202300389349100520 |
| 2022 | Herlev Og Gentofte Hospital Herlev | U | $275,000 | approved, future | UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS GIP IN PANCREATIC CELLS | 202300389349100520 |
| 2022 | The City of Hope Duarte, CA | U | $275,000 | approved, future | UNDERSTANDING GENETIC PROTECTION FROM T1D. | 202300389349100520 |
| 2022 | The City of Hope Duarte, CA | U | $275,000 | approved, future | UNDERSTANDING GENETIC PROTECTION FROM T1D. | 202300389349100520 |
| 2022 | Duke University Durham, NC | B | $275,000 | approved, future | UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS GIP IN PANCREATIC CELLS | 202300389349100520 |
| 2022 | Duke University Durham, NC | B | $275,000 | paid | UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS | 202300389349100520 |
| 2022 | Herlev Og Gentofte Hospital Herlev | U | $275,000 | paid | UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS | 202300389349100520 |
| 2022 | Children's Hospital of Philadelphia Philadelphia, PA | C | $272,676 | approved, future | CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM | 202300389349100520 |
| 2022 | Association Sante Diabete Grenoble | U | $272,362 | approved, future | DIABETES SUPPORT TO PEOPLE IN BURKINA FASO, MALI AND UNION OF COMOROS | 202300389349100520 |
| 2022 | Technische Universitt Dresden Dresden | U | $271,691 | paid | GENOMIC INFLUENCE OF MATERNAL T1D - UNDERSTANDING PROTECTION AGAINST T1D | 202300389349100520 |
| 2022 | Consorci Institut D'investigaciones Biomedicas August Barcelona | U | $270,828 | paid | EARLY DETECTION OF PERIANAL FISTULIZING DISEASE | 202300389349100520 |
| 2022 | Regents of the University of Mi Ann Arbor, MI | D | $270,158 | paid | UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE | 202300389349100520 |
| 2022 | Wyoming Department of Health Cheyenne, WY | U | $269,693 | paid | WYOMING FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $268,700 | paid | FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02 | 202300389349100520 |
| 2022 | University of Exeter Exeter | U | $268,565 | approved, future | STIMULATED GLUCAGON LEVELS BIOMARKER OF HYPOGLYCEMIA RISK IN T1D | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $268,151 | approved, future | INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNASEQ TO UNDERSTAND CD | 202300389349100520 |
| 2022 | Alimentiv Inc London | U | $267,835 | approved, future | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $267,814 | paid | SAFETY AND TOLERABILITY OF ORAL BFAHF-2 IN PEDIATRIC CROHNS DISEASE | 202300389349100520 |
| 2022 | Hannoversche Kinderheilanstalt Hannover | U | $267,694 | approved, future | FR1DA IN NORTH GERMANY: PRE-SYMPTOMATIC TYPE 1 DIABETES TESTING IN KIDS | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $266,200 | approved, future | FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02 | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $266,200 | approved, future | FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02 | 202300389349100520 |
| 2022 | White Pine County Hospital District Ely, NV | U | $265,831 | paid | INCREASED ULTRASOUND AVAILABILITY AND ABILITY FOR RURAL NORTHEAST NEVADA | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $264,341 | approved, future | SINGLE PERSISTENT ISLET AUTOANTIBODY PHENOTYPE: CUSTOMIZED RISK ANALYSIS | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $264,224 | paid | SINGLE PERSISTENT ISLET AUTOANTIBODY PHENOTYPE: CUSTOMIZED RISK ANALYSIS | 202300389349100520 |
| 2022 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $263,397 | paid | FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT | 202300389349100520 |
| 2022 | University of Oulu Oulu | U | $263,104 | approved, future | MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING | 202300389349100520 |
| 2022 | Public Health Solutions New York, NY | B | $262,335 | approved, future | NEW YORK CITY FUND FOR YOUTH AND FAMILY HOMELESSNESS | 202300389349100520 |
| 2022 | Consorci Institut D'investigaciones Biomedicas August Barcelona | U | $262,204 | paid | EARLY DETECTION OF PERIANAL FISTULIZING DISEASE | 202300389349100520 |
| 2022 | Consorci Institut D'investigaciones Biomedicas August Barcelona | U | $261,948 | approved, future | EARLY DETECTION OF PERIANAL FISTULIZING DISEASE | 202300389349100520 |
| 2022 | T1d Exchange Inc Boston, MA | U | $261,908 | approved, future | DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $261,030 | paid | RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE | 202300389349100520 |
| 2022 | Saint Louis University Saint Louis, MO | B | $260,774 | paid | NOVEL TARGET TO FIGHT ALPHA CELL DYSFUNCTION & STOP HYPOGLYCEMIA IN T1D | 202300389349100520 |
| 2022 | Alimentiv Inc London | U | $259,951 | approved, future | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Healthpartners Institute Minneapolis, MN | B | $258,500 | paid | DIRECT INTEGRATION OF CGM DATA INTO THE EMR | 202300389349100520 |
| 2022 | United Nations Development Programme New York, NY | C | $257,967 | paid | UNITED NATIONS MULTILATERAL AGENCY | 202300389349100520 |
| 2022 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $256,967 | paid | ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD | 202300389349100520 |
| 2022 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $256,967 | paid | ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $255,521 | approved, future | RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE | 202300389349100520 |
| 2022 | Stichting Pharmaccess International Amsterdam | U | $254,457 | paid | INVESTING IN QUALITY HEALTHCARE THROUGH SAFECARE | 202300389349100520 |
| 2022 | The Tel Aviv Jaffa Academic College Tel Aviv Yaffo | U | $253,818 | approved, future | SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $253,783 | approved, future | RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $251,789 | approved, future | IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN | 202300389349100520 |
| 2022 | Children's Hunger Fund Sylmar, CA | B | $250,409 | paid | MEDICAL AND ORPHAN CARE INITIATIVE IN ETHIOPIA | 202300389349100520 |
| 2022 | New York City Health and Hospitals Corporation New York, NY | C | $250,000 | paid | EXPRESSCARE PLATFORM UPDATE AND SERVICE DELIVERY TO HOMELESS PATIENTS | 202300389349100520 |
| 2022 | Rockefeller Philanthropy Advisors Inc New York, NY | C | $250,000 | paid | COVID COLLABORATIVE - INCREASING VACCINE UPTAKE IN RURAL AMERICA | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $250,000 | paid | DEVELOPING AN ISLET MODEL THAT MIMICS T1D | 202300389349100520 |
| 2022 | Regents of the University of Minnesota Minneapolis, MN | U | $250,000 | approved, future | PHASE 2: ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR T1D | 202300389349100520 |
| 2022 | Washington University St Louis, MO | C | $250,000 | paid | MANIPULATING ALPHA CELL SIGNALING TO RESTORE NORMAL GLUCAGON SECRETORY | 202300389349100520 |
| 2022 | Vivli Inc Cambridge, MA | C | $250,000 | paid | VIVLI TECHNICAL DEBT AMELIORATION | 202300389349100520 |
| 2022 | University of Miami Coral Gables, FL | U | $250,000 | paid | DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICE | 202300389349100520 |
| 2022 | American Pharmacists Association Foundation Washington, DC | B | $249,913 | paid | EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACY | 202300389349100520 |
| 2022 | Herlev Og Gentofte Hospital Herlev | U | $249,897 | paid | TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $249,337 | approved, future | IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN | 202300389349100520 |
| 2022 | Hebrew University of Jerusalem Jerusalem | D | $249,301 | paid | METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $249,169 | paid | EXERCISE EDUCATION AT NEW ONSET OF T1D | 202300389349100520 |
| 2022 | University of Florida Gainesville, FL | U | $248,597 | paid | T CELL RECEPTOR SEQUENCING IN T1D - BIOMARKER & TECHNOLOGY DEVELOPMENT | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $248,256 | approved, future | ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $248,256 | approved, future | ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $247,654 | approved, future | DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS | 202300389349100520 |
| 2022 | University of Cambridge Cambridge | U | $247,545 | paid | CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2 | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $246,663 | approved, future | AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT | 202300389349100520 |
| 2022 | Katholieke Universiteit Leuven Leuven | U | $246,662 | approved, future | AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT | 202300389349100520 |
| 2022 | University of Utah Salt Lake City, UT | B | $246,267 | paid | ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE | 202300389349100520 |
| 2022 | Universite Catholique de Louvain Louvainlaneuve | U | $246,186 | paid | DIRECT AND INDIRECT CAUSES FOR THE IMPAIRED GLUCAGON SECRETION IN T1D | 202300389349100520 |
| 2022 | The University of Oxford Oxford | U | $244,860 | paid | THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE | 202300389349100520 |
| 2022 | The University of Oxford Oxford | U | $244,860 | approved, future | THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE | 202300389349100520 |
| 2022 | The University of Oxford Oxford | U | $244,860 | approved, future | THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $244,200 | approved, future | ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $244,200 | approved, future | ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $243,550 | paid | LONGITUDINAL STUDY OF MYOELECTRIC GUTPRINT OF CROHNS PATIENTS | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $243,216 | approved, future | THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL PREVENTION | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $243,216 | approved, future | THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL & PREVENTION | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $242,153 | approved, future | THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL & PREVENTION | 202300389349100520 |
| 2022 | Project Nyame Nsa Ltd Manhasset, NY | U | $241,600 | approved, future | PROJECT NYAME NSA ZAMBIA EXPANSION | 202300389349100520 |
| 2022 | The Rector and Visitors of the University of Virginia Charlottesville, VA | C | $241,490 | paid | TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS | 202300389349100520 |
| 2022 | Jdrf Australia Sydney | U | $239,784 | paid | ENDIA EARLY TO MID-CAREER SCIENCE ACCELERATOR AWARDS 2021 | 202300389349100520 |
| 2022 | The Chinese University of Hong Kong Shatin | U | $239,672 | paid | IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN | 202300389349100520 |
| 2022 | Johns Hopkins University Baltimore, MD | U | $239,373 | paid | A MULTIDISCIPLINARY BIOENGINEERING APPROACH TO FISTULA-IN-ANO IN CROHNS | 202300389349100520 |
| 2022 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $236,320 | paid | MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS | 202300389349100520 |
| 2022 | Children's Hospital Medical Center Cincinnati, OH | B | $235,507 | approved, future | PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS | 202300389349100520 |
| 2022 | Vayu Health Portola Valley, CA | B | $233,495 | approved, future | VAYU FEASIBILITY PILOT | 202300389349100520 |
| 2022 | University at Buffalo Pediatric Associates P C Buffalo, NY | D | $233,094 | approved, future | TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $232,672 | paid | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Jdrf Australia Sydney | U | $232,577 | approved, future | ENDIA EARLY TO MID-CAREER SCIENCE ACCELERATOR AWARDS 2021 | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $231,849 | approved, future | INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNASEQ TO UNDERSTAND CD | 202300389349100520 |
| 2022 | Vanderbilt University Nashville, TN | C | $231,831 | paid | UNDERSTANDING CALCIUM SIGNALING IN ALPHA CELLS AND HOW THEY WORK IN T1D | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $230,209 | approved, future | DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $228,012 | paid | EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D | 202300389349100520 |
| 2022 | Ideoorg San Francisco, CA | U | $227,950 | approved, future | HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES. | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $224,138 | paid | COMPLEMENT SYSTEM IN INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $223,818 | approved, future | COMPLEMENT SYSTEM IN INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY | 202300389349100520 |
| 2022 | Pulitzer Center On Crisis Reporting Washington, DC | C | $223,410 | paid | BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION | 202300389349100520 |
| 2022 | The Max Stern Academic College of Emek Yezreel Yezreel Valley | U | $220,000 | paid | OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG | 202300389349100520 |
| 2022 | The Max Stern Academic College of Emek Yezreel Yezreel Valley | U | $220,000 | approved, future | OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $220,000 | approved, future | VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $220,000 | paid | VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES | 202300389349100520 |
| 2022 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $220,000 | approved, future | VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES | 202300389349100520 |
| 2022 | The Max Stern Academic College of Emek Yezreel Yezreel Valley | U | $220,000 | approved, future | OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG | 202300389349100520 |
| 2022 | Center for Excellence in Health Care Journalism Columbia, MO | C | $219,995 | approved, future | TRAINING AND DEVELOPMENT OF HEALTH CARE JOURNALISTS AND HEALTH REPORTING | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $219,514 | approved, future | PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY | 202300389349100520 |
| 2022 | Montana Department Public Health and Human Services Helena, MT | U | $219,190 | paid | MONTANA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Association of Diabetes Care & Education Specialists Chicago, IL | B | $216,544 | paid | AADE TECHNOLOGY INSTITUTE: DANA - DIABETES ADVANCED NETWORK ACCESS | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $216,002 | approved, future | PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY | 202300389349100520 |
| 2022 | New Destiny Housing Corporation New York, NY | B | $215,030 | approved, future | AFTERCARE INTERVENTION TO IMPROVE HOUSING & HEALTH STABILITY | 202300389349100520 |
| 2022 | Universite Libre de Bruxelles Brussels | U | $213,602 | approved, future | DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS. | 202300389349100520 |
| 2022 | Universite Libre de Bruxelles Brussels | U | $213,582 | approved, future | DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS. | 202300389349100520 |
| 2022 | Sanford Research Sioux Fall, SD | C | $212,565 | approved, future | SANFORD PLEDGE: PHASES 1 AND 2 | 202300389349100520 |
| 2022 | Technische Universitt Dresden Dresden | U | $212,157 | paid | SUPPORT SCREENING FOR ISLET AUTOANTIBODIES IN CHILDREN. | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $211,815 | approved, future | PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY | 202300389349100520 |
| 2022 | Technische Universitt Dresden Dresden | U | $210,829 | approved, future | GENOMIC INFLUENCE OF MATERNAL T1D - UNDERSTANDING PROTECTION AGAINST T1D | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $210,638 | approved, future | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Asian Health Care Foundation Hyderabad | U | $210,551 | approved, future | ACCESS TO CROHNS DIAGNOSTICS IN INDIA FOR PATIENTS LIVING IN POVERTY | 202300389349100520 |
| 2022 | St Luke Health Care Foundation West Chicago, IL | C | $210,306 | paid | TEACHING HOSPITAL INFRASTRUCTURE IMPROVEMENTS | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $210,228 | approved, future | NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $210,228 | paid | NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE | 202300389349100520 |
| 2022 | Humboldt County Hospital District Winnemucca, NV | U | $209,393 | paid | ULTRASOUND EQUIPMENT | 202300389349100520 |
| 2022 | Association Sante Diabete Grenoble | U | $205,984 | approved, future | DIABETES SUPPORT TO PEOPLE IN BURKINA FASO, MALI AND UNION OF COMOROS | 202300389349100520 |
| 2022 | New York University New York, NY | B | $205,596 | approved, future | EVALUATION OF INTERVENTIONS FOR COLLABORATIVE FOR HOMELESS HEALTHCARE | 202300389349100520 |
| 2022 | Crohn's & Colitis Foundation Inc New York, NY | B | $205,000 | paid | SUPPORT FOR CCF'S CROHNS AND COLITIS CONGRESS- JANUARY, 2022 | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $204,837 | approved, future | PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY | 202300389349100520 |
| 2022 | University of Utah Salt Lake City, UT | B | $203,988 | approved, future | ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $202,791 | approved, future | PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY | 202300389349100520 |
| 2022 | The Rector and Visitors of the University of Virginia Charlottesville, VA | C | $202,177 | approved, future | TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $202,073 | approved, future | EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $200,041 | approved, future | PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY | 202300389349100520 |
| 2022 | Care for the Homeless New York, NY | B | $200,000 | paid | NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $200,000 | approved, future | ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES | 202300389349100520 |
| 2022 | The Diatribe Foundation San Francisco, CA | C | $200,000 | paid | DIATRIBE LEARN | 202300389349100520 |
| 2022 | Project Renewal Inc New York, NY | B | $200,000 | paid | NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $200,000 | approved, future | ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES | 202300389349100520 |
| 2022 | Region Hovedstaden Hillerd | U | $200,000 | paid | IDENTIFICATION/SCREENING OF NOVEL GLUCAGONOTROPIC ALPHA-CELL RECEPTORS | 202300389349100520 |
| 2022 | Citizens Housing and Planning Council of New York Inc New York, NY | B | $200,000 | approved, future | EDUCATION FOR NYC POLICYMAKERS ON HOUSING INITIATIVES TO IMPROVE HEALTH | 202300389349100520 |
| 2022 | Shatterproof a Nonprofit Corp Norwalk, CT | U | $200,000 | paid | GENERAL OPERATING SUPPORT | 202300389349100520 |
| 2022 | Northern Westchester Hospital Association Mount Kisco, NY | C | $200,000 | paid | MATERNAL CHILD HEALTH UNIT FACILITIES RENOVATION | 202300389349100520 |
| 2022 | Shatterproof a Nonprofit Corp Norwalk, CT | U | $200,000 | paid | GENERAL OPERATING SUPPORT | 202300389349100520 |
| 2022 | For Inspiration and Recognition of Science Technology Manchester | U | $200,000 | approved, future | INSPIRE YOUNG PEOPLE TO BE SCIENCE AND TECHNOLOGY LEADERS | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $200,000 | paid | ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES | 202300389349100520 |
| 2022 | Northern Westchester Hospital Association Mount Kisco, NY | C | $200,000 | approved, future | MATERNAL CHILD HEALTH UNIT FACILITIES RENOVATION | 202300389349100520 |
| 2022 | Youth Development Organization Inc Lawrence, MA | B | $200,000 | approved, future | CAPACITY BUILDING PROJECT SUPPORT 2022 | 202300389349100520 |
| 2022 | Ideoorg San Francisco, CA | U | $200,000 | paid | HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES. | 202300389349100520 |
| 2022 | New York-Presbyterian Fund Inc New York, NY | C | $200,000 | paid | IMPROVING CARE FOR UNDERSERVED CHILDREN WITH T1D | 202300389349100520 |
| 2022 | Center for Urban Community Services Inc New York, NY | U | $200,000 | paid | NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE | 202300389349100520 |
| 2022 | Fund for Public Housing Inc New York, NY | B | $200,000 | paid | STRATEGIC PLANNING AND DEMONSTRATION PROJECT | 202300389349100520 |
| 2022 | Youth Development Organization Inc Lawrence, MA | B | $200,000 | approved, future | CAPACITY BUILDING PROJECT SUPPORT 2022 | 202300389349100520 |
| 2022 | Ideoorg San Francisco, CA | U | $200,000 | approved, future | HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES. | 202300389349100520 |
| 2022 | For Inspiration and Recognition of Science Technology Manchester, NH | C | $200,000 | paid | INSPIRE YOUNG PEOPLE TO BE SCIENCE AND TECHNOLOGY LEADERS | 202300389349100520 |
| 2022 | Citizens Housing and Planning Council of New York Inc New York, NY | B | $200,000 | paid | EDUCATION FOR NYC POLICYMAKERS ON HOUSING INITIATIVES TO IMPROVE HEALTH | 202300389349100520 |
| 2022 | Dartmouth- Hitchcock Clinic Lebanon, NH | B | $197,461 | approved, future | CAPACITY BUILDING FOR VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM | 202300389349100520 |
| 2022 | King's College London London | U | $195,494 | approved, future | IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE | 202300389349100520 |
| 2022 | Dartmouth- Hitchcock Clinic Lebanon, NH | B | $195,140 | paid | CAPACITY BUILDING FOR VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM | 202300389349100520 |
| 2022 | New York University New York, NY | B | $194,404 | paid | EVALUATION OF INTERVENTIONS FOR COLLABORATIVE FOR HOMELESS HEALTHCARE | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $191,883 | approved, future | THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD | 202300389349100520 |
| 2022 | Montana Department of Health and Human Services Helena, MT | U | $191,663 | paid | MONTANA FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | De la Salle Solidarietainternazionale Onlus Rome | U | $191,462 | approved, future | ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY | 202300389349100520 |
| 2022 | Mcgill University Montreal | U | $189,596 | approved, future | THE HUMAN CELL ATLAS: ETHICS AND DATA GOVERNANCE | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $188,736 | paid | THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD | 202300389349100520 |
| 2022 | Iowa Department of Public Health Des Moines, IA | U | $186,944 | approved, future | IOWA FIRST RESPONDER AED INITIATIVE | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $186,777 | approved, future | THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD | 202300389349100520 |
| 2022 | Governing Council of the University of Toronto Toronto | D | $185,460 | approved, future | GLUCOSE RESPONSIVE GLUCAGON MICRONEEDLE PATCH - HYPOGLYCEMIA PREVENTION | 202300389349100520 |
| 2022 | The Sderot Development Foundation Sderot | U | $184,286 | approved, future | SDEROT RESILIENCE COMPLEX, RESILIENCE CENTER AND PARENTHOOD HOUSE | 202300389349100520 |
| 2022 | Wyoming Department of Health Cheyenne, WY | U | $183,693 | approved, future | WYOMING FIRST RESPONDER AED PROJECT | 202300389349100520 |
| 2022 | Americares Foundation Inc Stamford, CT | C | $183,200 | paid | OXYGEN FOR SUNTRESO HOSPITAL | 202300389349100520 |
| 2022 | Stanford University Stanford, CA | C | $183,151 | paid | EXERCISE EDUCATION AT NEW ONSET OF T1D | 202300389349100520 |
| 2022 | Center for Excellence in Health Care Journalism Columbia, MO | C | $180,005 | paid | TRAINING AND DEVELOPMENT OF HEALTH CARE JOURNALISTS AND HEALTH REPORTING | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $178,454 | approved, future | EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D | 202300389349100520 |
| 2022 | Institut Nationale de la Sante Et de la Recherche Medicale Paris | U | $178,286 | paid | BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION | 202300389349100520 |
| 2022 | State of South Dakota Pierre, SD | U | $178,000 | paid | SOUTH DAKOTA FIRST RESPONDER AUTOMATED EXTERNAL DEFIBRILLATOR PROJECT | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $177,281 | approved, future | COVID-19 VACCINE RESPONSES IN PATIENTS WITH IBD | 202300389349100520 |
| 2022 | Consorci Institut D'investigaciones Biomedicas August Barcelona | U | $177,122 | approved, future | EARLY DETECTION OF PERIANAL FISTULIZING DISEASE | 202300389349100520 |
| 2022 | Crohn's Colitis Cure Sydney | U | $175,233 | paid | DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE | 202300389349100520 |
| 2022 | Rockefeller Philanthropy Advisors Inc New York, NY | C | $175,000 | paid | FUNDING TO SUPPORT COVID COLLABORATIVE - BEREAVED CHILDREN PROJECT | 202300389349100520 |
| 2022 | The Milken Institute Santa Monica, CA | B | $174,998 | paid | CURES FOR LIFE: PATIENT ACCESS TO CELL AND GENE THERAPY | 202300389349100520 |
| 2022 | University of Iowa Iowa City, IA | U | $174,321 | paid | RUPRI HEALTH PANEL SUPPORT | 202300389349100520 |
| 2022 | North Dakota Department of Health Bismarck, ND | U | $173,689 | approved, future | NORTH DAKOTA LAW ENFORCEMENT AED PROJECT | 202300389349100520 |
| 2022 | Albert Einstein College of Medicine Bronx, NY | B | $173,613 | approved, future | SUPPLEMENTAL SUPPORT FOR T1DTECHCHW | 202300389349100520 |
| 2022 | Centre Hospitalier Regional de Nancy Nancy | U | $173,555 | paid | PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE | 202300389349100520 |
| 2022 | Universitair Medisch Centrum Utrecht Utrecht | U | $173,250 | approved, future | EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD | 202300389349100520 |
| 2022 | Universitair Medisch Centrum Utrecht Utrecht | U | $173,250 | paid | EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD | 202300389349100520 |
| 2022 | Universitair Medisch Centrum Utrecht Utrecht | U | $173,250 | approved, future | EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD | 202300389349100520 |
| 2022 | International Bowel Ultrasound Group Ev Munster | U | $172,967 | approved, future | POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES | 202300389349100520 |
| 2022 | Albert Einstein College of Medicine Bronx, NY | B | $168,556 | approved, future | SUPPLEMENTAL SUPPORT FOR T1DTECHCHW | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $166,933 | paid | COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS | 202300389349100520 |
| 2022 | The University of Western Australia Crawley | U | $166,923 | approved, future | CGM ASSESSMENTS OF ENDIA CHILDREN | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $165,855 | paid | COVID-19 VACCINE RESPONSES IN PATIENTS WITH IBD | 202300389349100520 |
| 2022 | Crohn's and Colitis Canada Toronto | U | $165,648 | paid | IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS | 202300389349100520 |
| 2022 | The Weizmann Institute of Science Rehovot | D | $165,000 | paid | THE QUANTUM MATERIALS DEVICES FABRICATION LAB | 202300389349100520 |
| 2022 | Institut Nationale de la Sante Et de la Recherche Medicale Paris | U | $164,338 | approved, future | BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION | 202300389349100520 |
| 2022 | Albert Einstein College of Medicine Bronx, NY | B | $163,648 | approved, future | SUPPLEMENTAL SUPPORT FOR T1DTECHCHW | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $162,082 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY | 202300389349100520 |
| 2022 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $159,838 | approved, future | EXERCISE IN DIABETES INITIATIVE: LARGE ADULT STUDY | 202300389349100520 |
| 2022 | Galilee Medical Center Nahariya | U | $157,000 | paid | PURCHASE OF TWO ECMO MACHINES FOR GALILEE MEDICAL CENTER | 202300389349100520 |
| 2022 | Yale University New Haven, CT | U | $156,907 | paid | THERAPEUTIC TARGETS AT THE HOST MICROBIOTA INTERFACE FOR FIBROSIS | 202300389349100520 |
| 2022 | Monroe County Hospital Albia, IA | U | $156,759 | paid | EPHARMACY AT MONROE COUNTY HOSPITAL & CLINICS | 202300389349100520 |
| 2022 | American Gastroenterological Association Institute Bethesda, MD | B | $155,930 | approved, future | SPECIALIZED IBD TRAINING FOR ADVANCE PRACTICE PROVIDERS | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $155,544 | approved, future | STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH CONSORTIUM | 202300389349100520 |
| 2022 | Hillel Yaffe Medical Center Hadera | U | $155,418 | paid | PURCHASE TWO ECMO MACHINES FOR HILLEL YAFFE MEDICAL CENTER | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $155,376 | approved, future | DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR | 202300389349100520 |
| 2022 | North Dakota Department of Health Bismarck, ND | U | $153,789 | paid | NORTH DAKOTA LAW ENFORCEMENT AED PROJECT | 202300389349100520 |
| 2022 | Centre Hospitalier Regional de Nancy Nancy | U | $153,102 | approved, future | PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE | 202300389349100520 |
| 2022 | The University of Oxford Oxford | U | $152,072 | paid | STUDY OF COVID-19 ANTIBODY RESPONSE UNDER SUSTAINED IMMUNE SUPPRESSION | 202300389349100520 |
| 2022 | Children's Hunger Fund Sylmar, CA | B | $151,800 | approved, future | FOOD SUPPORT IN ETHIOPIA AND ZAMBIA | 202300389349100520 |
| 2022 | Mayo Clinic Rochester, MN | U | $151,705 | approved, future | DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD | 202300389349100520 |
| 2022 | Ziv Medical Center Zefat Zefat | U | $151,611 | paid | PURCHASE OF TWO ECMO MACHINES FOR ZIV MEDICAL CENTER | 202300389349100520 |
| 2022 | South Lincoln Hospital District Kemmerer, WY | D | $151,487 | approved, future | TELE-EMERGENCY SERVICE AT SOUTH LINCOLN MEDICAL CENTER | 202300389349100520 |
| 2022 | Pawnee County Memorial Hospital Pawnee City, NE | U | $150,545 | paid | ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL | 202300389349100520 |
| 2022 | Fund for Public Health in New York Inc New York, NY | B | $150,467 | approved, future | NYC VACCINE EQUITY PARTNER ENGAGEMENT PROJECT | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $150,000 | approved, future | HELMSLEY AND JDRF CO-FUNDED WORKSHOPS | 202300389349100520 |
| 2022 | Ideoorg San Francisco, CA | U | $150,000 | paid | HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES. | 202300389349100520 |
| 2022 | National Academy of Sciences Washington, DC | C | $150,000 | approved, future | STRENGTHENING MINORITY SERVING INSTITUTIONS | 202300389349100520 |
| 2022 | Jdrf International New York, NY | U | $150,000 | approved, future | HELMSLEY AND JDRF CO-FUNDED WORKSHOPS | 202300389349100520 |
| 2022 | The Milken Institute Santa Monica, CA | B | $150,000 | paid | SUPPORTS TO CREATE A STRATEGIC ROADMAP FOR T1D TO INCLUDE SCREENING | 202300389349100520 |
| 2022 | American Diabetes Association Inc Arlington, VA | B | $150,000 | paid | CGM SUPPORT FOR ADAS HEALTH EQUITY NOW 4TH NETWORK - COLUMBUS STUDY | 202300389349100520 |
| 2022 | Bipartisan Policy Center Inc Washington, DC | B | $149,200 | paid | RURAL HEALTH CARE TASK FORCE | 202300389349100520 |
| 2022 | Beyond Type 1 San Carlos, CA | D | $149,167 | approved, future | DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3 | 202300389349100520 |
| 2022 | Beyond Type 1 San Carlos, CA | D | $149,166 | approved, future | DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3 | 202300389349100520 |
| 2022 | Institut Integrated Biobank of Luxembourg Dudelange | U | $148,458 | approved, future | BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL | 202300389349100520 |
| 2022 | Vivli Inc Cambridge, MA | C | $147,174 | paid | PUBLICLY SHARING THE DATA FROM EXERCISE AND T1D STUDIES | 202300389349100520 |
| 2022 | Universite Catholique de Louvain Louvainlaneuve | U | $147,087 | approved, future | STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D | 202300389349100520 |
| 2022 | Vanderbilt University Medical Center Nashville, TN | C | $146,933 | approved, future | COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $146,811 | paid | NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE | 202300389349100520 |
| 2022 | Vayu Health Portola Valley, CA | B | $146,667 | approved, future | VAYU FEASIBILITY PILOT | 202300389349100520 |
| 2022 | Vayu Health Portola Valley, CA | B | $146,667 | approved, future | VAYU FEASIBILITY PILOT | 202300389349100520 |
| 2022 | Vayu Health Portola Valley, CA | B | $146,666 | approved, future | VAYU FEASIBILITY PILOT | 202300389349100520 |
| 2022 | University of Dundee Dundee | U | $145,758 | paid | HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA | 202300389349100520 |
| 2022 | Universite Catholique de Louvain Louvainlaneuve | U | $144,419 | paid | STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $143,000 | paid | POPULATION-BASED ANALYSES OF IBD USING ADMINISTRATIVE DATABASE | 202300389349100520 |
| 2022 | Rambam Health Corporation Haifa | D | $142,800 | paid | POINT OF CARE ASSAY FOR SERUM NEUTRALIZING ANTI-IFX ANTIBODIES | 202300389349100520 |
| 2022 | Lander County Hospital District Battle Mountain, NV | U | $142,265 | paid | RADIOLOGY EQUIPMENT FOR BATTLE MOUNTAIN GENERAL HOSPITAL | 202300389349100520 |
| 2022 | Bridges to Prosperity Inc Denver, CO | D | $142,110 | approved, future | ETHIOPIA ASSESSMENT OF BRIDGE INFRASTRUCTURE | 202300389349100520 |
| 2022 | Bridges to Prosperity Inc Denver, CO | D | $142,110 | approved, future | ZAMBIA ASSESSMENT OF BRIDGE INFRASTRUCTURE | 202300389349100520 |
| 2022 | Banner Health Fallon, NV | U | $139,574 | approved, future | BANNER CHURCHILL COMMUNITY HOSPITAL ULTRASOUND INITIATIVE | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $137,417 | approved, future | INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $137,153 | approved, future | INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY | 202300389349100520 |
| 2022 | Shaare Zedek Medical Center Jerusalem | D | $137,000 | paid | POPULATION-BASED ANALYSES OF IBD USING ADMINISTRATIVE DATABASE | 202300389349100520 |
| 2022 | University of Dundee Dundee | U | $133,804 | approved, future | HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA | 202300389349100520 |
| 2022 | Stiftelsenforskning Avseende Inflammatoriska Tarmsjukdom Orebro | U | $132,000 | approved, future | HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD | 202300389349100520 |
| 2022 | Stiftelsen Forskning Avseende Inflammatoriska Tarmsjukdom Orebro | U | $132,000 | approved, future | HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD | 202300389349100520 |
| 2022 | Stiftelsen Utbildning Avseende Inflammatoriska Tarmsjukdom Orebro | U | $132,000 | approved, future | HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD | 202300389349100520 |
| 2022 | The University of Oxford Oxford | U | $131,216 | paid | PHARMACOLOGICAL MODULATION TO ADDRESS GLUCAGON SECRETION IN T1D | 202300389349100520 |
| 2022 | Monument Health Network Inc Sturgis, SD | C | $129,650 | paid | EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL | 202300389349100520 |
| 2022 | University of California San Francisco San Francisco, CA | U | $128,169 | paid | ISLET AUTOIMMUNITY IN PATIENTS WITH STAT GAIN-OF-FUNCTION MUTATIONS | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $127,077 | approved, future | INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY | 202300389349100520 |
| 2022 | University of Zurich Zurich | U | $126,830 | approved, future | GENERATE BISPECIFIC INTERLEUKIN-2 IMMUNOTHERAPY TO TREAT T1D MELLITUS | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $126,154 | approved, future | INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY | 202300389349100520 |
| 2022 | Mayo Clinic Rochester, MN | U | $124,891 | paid | 2019-2021 MILITARY SCIENCES MEDICAL TRAINING/SUPPORT PROJECT (ARIZONA) | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $122,854 | approved, future | INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY | 202300389349100520 |
| 2022 | Dundy County Hospital Benkelman, NE | C | $121,593 | approved, future | TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL | 202300389349100520 |
| 2022 | Uppsala Universitet Uppsala | U | $121,182 | paid | ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $121,036 | approved, future | THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD | 202300389349100520 |
| 2022 | Rambam Health Corporation Haifa | D | $120,355 | paid | POINT OF CARE ASSAY FOR SERUM NEUTRALIZING ANTI-IFX ANTIBODIES | 202300389349100520 |
| 2022 | First Affiliated Hospital of Sun Yat-Sen University Guangzhou | U | $120,000 | paid | INDUSTRIALIZATION RELATED ENVIRONMENTAL CHANGES & MICROBIOME ALTERATIONS | 202300389349100520 |
| 2022 | Grantmakers in Health Washington, DC | B | $119,803 | approved, future | GRANTMAKERS IN HEALTH EFFECTIVE PHILANTHROPY FUND | 202300389349100520 |
| 2022 | The Governors of the University of Calgary Calgary | D | $119,554 | approved, future | INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY | 202300389349100520 |
| 2022 | The Regents of the University of Colorado Denver Aurora, CO | D | $119,036 | paid | DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR | 202300389349100520 |
| 2022 | Lucas County Health Center Chariton, IA | D | $118,418 | paid | AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER | 202300389349100520 |
| 2022 | University of Zurich Zurich | U | $118,250 | paid | GENERATE BISPECIFIC INTERLEUKIN-2 IMMUNOTHERAPY TO TREAT T1D MELLITUS | 202300389349100520 |
| 2022 | Council On the Environment Inc New York, NY | B | $116,600 | paid | INTER-GENERATIONAL, VIABLE GREENSPACE IN NYCHA COMMUNITIES | 202300389349100520 |
| 2022 | Alimentiv Inc London | U | $116,515 | paid | STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $115,500 | paid | VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $115,500 | approved, future | VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI | 202300389349100520 |
| 2022 | Cedars-Sinai Medical Center Los Angeles, CA | B | $115,500 | approved, future | VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI | 202300389349100520 |
| 2022 | King's College London London | U | $115,097 | approved, future | T CELL RECEPTOR SEQUENCING IN T1D - BIOMARKER & TECHNOLOGY DEVELOPMENT | 202300389349100520 |
| 2022 | Franciscan Care Services Inc West Point, NE | B | $114,632 | paid | TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE | 202300389349100520 |
| 2022 | Clalit Health Services Tel Aviv | U | $112,000 | paid | EARLY CROHNS DISEASE: UNDERSTANDING PATHOGENESIS, BEHAVIOR, RESPONSE | 202300389349100520 |
| 2022 | Madison County Memorial Hospital Winterset, IA | U | $111,961 | paid | IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM | 202300389349100520 |
| 2022 | The Cleveland Clinic Foundation Cleveland, OH | C | $111,750 | approved, future | DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD | 202300389349100520 |
| 2022 | University of Toledo Toledo, OH | B | $110,480 | paid | TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH | 202300389349100520 |
| 2022 | University of Toledo Toledo, OH | B | $110,480 | approved, future | TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH | 202300389349100520 |
| 2022 | 4youandme Seattle, WA | U | $110,128 | approved, future | WEARABLES TO MEASURE STRESS AND FORECAST CROHNS SYMPTOMS | 202300389349100520 |
| 2022 | Columbia University New York, NY | B | $110,040 | paid | POVERTY TRACKER SURVEY: HEALTHCARE NEEDS & USE OF LOW-INCOME NEW YORKERS | 202300389349100520 |
| 2022 | The University of Edinburgh Edinburgh | U | $109,128 | approved, future | DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D | 202300389349100520 |
| 2022 | Simulation in Motion Montana Inc Helena, MT | B | $108,298 | approved, future | CAPACITY BUILDING TOWARD A SUSTAINABLE SIMULATION IN MOTION MONTANA | 202300389349100520 |
| 2022 | University of California San Francisco San Francisco, CA | U | $108,185 | paid | VALIDATING A CLASS OF DRUGS THAT MAY PROTECT BETA CELLS IN T1D | 202300389349100520 |
| 2022 | Mayo Clinic Rochester, MN | U | $103,827 | approved, future | STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH CONSORTIUM | 202300389349100520 |
| 2022 | Centre Hospitalier Regional de Nancy Nancy | U | $103,796 | approved, future | PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE | 202300389349100520 |
| 2022 | University of Birmingham Birmingham | U | $102,647 | paid | ANTIGEN SPECIFIC IMMUNOTHERAPY IN TYPE 1 DIABETES | 202300389349100520 |
| 2022 | The University of Western Australia Crawley | U | $102,133 | paid | CGM ASSESSMENTS OF ENDIA CHILDREN | 202300389349100520 |
| 2022 | New Venture Fund Washington, DC | B | $102,000 | paid | TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024) | 202300389349100520 |
| 2022 | New York University New York, NY | B | $101,043 | approved, future | ANALYSIS OF MEDICAID DATA TO IMPROVE CARE FOR HOMELESS PATIENTS | 202300389349100520 |
| 2022 | The Weizmann Institute of Science Rehovot | D | $100,904 | paid | PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IN CROHNS | 202300389349100520 |
| 2022 | Boulder City Hospital Inc Boulder City, NV | B | $100,838 | paid | BOULDER CITY HOSPITAL ULTRASOUND INITIATIVE | 202300389349100520 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.